Nutra Pharma (NPHC) 10-K 1 Jul 21 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Jul. 01, 2021	Jun. 30, 2019
Cover [Abstract]
Entity Registrant Name	NUTRA PHARMA CORP
Entity Central Index Key	0001119643
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 2,385,792
Entity Common Stock, Shares Outstanding		7,260,119,714
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash
Accounts receivable	32,479	17,065
Inventory, current portion	8,177	35,302
Prepaid expenses and other current assets	17,150	63,000
Total current assets	57,806	115,367
Inventory, less current portion	52,183
Property and equipment, net	6,763	10,500
Operating lease right-of-use assets	207,530
Security deposit	15,550	15,550
Total assets	339,832	141,417
Current liabilities:
Accounts payable	583,226	475,409
Accrued expenses	612,547	831,849
Accrued payroll due to officers	1,249,393	1,050,993
Accrued interest to related parties	159,555	141,808
Due to officer	122,812	186,497
Derivative liabilities	835,868	1,468
Other debt, net of discount, current portion	7,352,954	3,338,576
Operating lease obligations, current portion	73,278
Total current liabilities	10,989,633	6,026,600
Promissory note, less current portion		51,410
Convertible note, less current portion	907,912
Operating lease obligations, less current portion	143,322
Total liabilities	12,040,867	6,078,010
Stockholders' deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at December 31, 2019 and 2018	3,000	3,000
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 5,876,746,111 and 4,046,746,110 shares issued and outstanding at December 31, 2019 and 2018	5,876,746	4,046,746
Additional paid-in capital	50,283,503	51,286,503
Accumulated deficit	(67,864,284)	(61,272,842)
Total stockholders' deficit	(11,701,035)	(5,936,593)
Total liabilities and stockholders' deficit	$ 339,832	$ 141,417

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	8,000,000,000	8,000,000,000
Common stock, shares issued	5,876,746,111	4,046,746,110
Common stock, shares outstanding	5,876,746,111	4,046,746,110
Series A Preferred Stock [Member]
Preferred stock, shares issued	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net sales	$ 104,393	$ 130,596
Cost of sales	(45,730)	(68,777)
Change in reserve for supplier advances for purchases	(23,948)	(47,757)
Gross profit	34,715	14,062
Operating expenses:
Selling, general and administrative - including stock based compensation of $71,500 and $70,000 for the years ended December 31, 2019 and 2018, respectively	1,202,819	1,387,454
Bad debt expense (related party of $59,000 and $505,470)	61,789	505,470
Total operating expenses	1,264,608	1,892,924
Loss from operations	(1,229,893)	(1,878,862)
Other income (expenses)
Interest expense	(244,278)	(574,334)
Interest expense to related parties	(17,747)	(15,772)
Change in fair value of convertible notes and derivatives	(5,184,445)	(2,146,950)
Stock issued for loan modification	(7,700)	(174,535)
Gain on settlement of debt, accounts payable, and accrued expenses, net	92,621	905,758
Total other income (expenses)	(5,361,549)	(2,005,833)
Loss before income taxes	(6,591,442)	(3,884,695)
Provision for income taxes
Net loss	$ (6,591,442)	$ (3,884,695)
Net loss per share - basic and diluted	$ 0	$ 0
Weighted average number of shares outstanding during the year - basic and diluted	4,710,306,385	3,187,272,679

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock based compensation	$ 71,500	$ 70,000
Bad debt expense	61,789	505,470
Rik Deitsch [Member]
Bad debt expense	$ 59,000	$ 505,470

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,000	$ 2,032,234	$ 49,942,719	$ (57,388,147)	$ (5,410,194)
Balance, shares at Dec. 31, 2017	3,000,000	2,032,233,701
Issuance of common stock in exchange for services to consultants		$ 100,000	20,000		120,000
Issuance of common stock in exchange for services to consultants, shares		100,000,000
Common stock issued for debt modification and penalty		$ 139,782	34,753		174,535
Common stock issued for debt modification and penalty, shares		139,782,409
Common stock issued for conversion of debt		$ 1,399,680	1,034,772		2,434,452
Common stock issued for conversion of debt, shares		1,399,680,000
Common stock issued for settlement of accounts payable and debt		$ 335,300	12,750		348,050
Common stock issued for settlement of accounts payable and debt, shares		335,300,000
Common stock issued with Debt--Debt discount		$ 39,750	(7,604)		32,146
Common stock issued with Debt--Debt discount, shares		39,750,000
Beneficial conversion features			249,113		249,113
Net loss				(3,884,695)	(3,884,695)
Balance at Dec. 31, 2018	$ 3,000	$ 4,046,746	51,286,503	(61,272,842)	(5,936,593)
Balance, shares at Dec. 31, 2018	3,000,000	4,046,746,110
Issuance of common stock in exchange for services to consultants		$ 135,000	(105,000)		30,000
Issuance of common stock in exchange for services to consultants, shares		135,000,000
Common stock issued for debt modification and penalty		$ 22,000	(14,300)		7,700
Common stock issued for debt modification and penalty, shares		22,000,000
Common stock issued for conversion of debt		$ 750,000	(475,000)		275,000
Common stock issued for conversion of debt, shares		750,000,000
Common stock issued for settlement of accounts payable and debt		$ 881,000	(394,600)		486,400
Common stock issued for settlement of accounts payable and debt, shares		881,000,000
Common stock issued with Debt--Debt discount		$ 42,000	(29,617)		12,383
Common stock issued with Debt--Debt discount, shares		42,000,001
Warrants issued with Debt--Debt discount			15,517		15,517
Net loss				(6,591,442)	(6,591,442)
Balance at Dec. 31, 2019	$ 3,000	$ 5,876,746	$ 50,283,503	$ 67,846,284	$ (11,701,035)
Balance, shares at Dec. 31, 2019	3,000,000	5,876,746,111

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (6,591,442)	$ (3,884,695)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in reserve for supplier advances for purchases	23,948	47,757
Bad debt expense	61,789	505,470
Accrued interest expense for amount due to officer	6,330	7,674
Gain on settlement of debt, accounts payable and accrued expenses	(92,621)	(905,758)
Depreciation	3,737	5,963
Stock-based compensation	71,500	70,000
Stock-based loan modification cost	7,700	174,535
Change in fair value of convertible notes and derivatives	5,184,445	2,146,950
Amortization of loan discount	100,810	378,754
Amortization of operating lease right-of-use assets	73,645
Changes in operating assets and liabilities:
Increase in accounts receivable	(18,203)	(1,922)
Increase in inventory	(25,058)	(15,160)
Increase in prepaid expenses and other current assets	(19,598)	(8,257)
Increase in accounts payable	107,817	86,567
Increase in accrued expenses	209,970	184,391
Increase in accrued payroll due to officers	198,400	214,500
Decrease in deferred revenue		(22,490)
Increase in accrued interest to related parties	17,747	15,772
Decrease in operating lease obligations	(64,575)
Net cash used in operating activities	(743,659)	(999,949)
Cash flows from financing activities:
Loans from officer	5,000	105,900
Repayment of officer loans	(134,015)	(162,775)
Proceeds from convertible notes	782,374	1,101,800
Repayment of convertible notes	(13,500)	(3,000)
Other advances from an unrelated third party	175,000
Repayments of other notes payable	(71,200)	(41,976)
Net cash provided by financing activities	743,659	999,949
Net increase in cash
Cash - beginning of period
Cash - end of period
Supplemental Cash Flow Information:
Cash paid for interest	661	5,425
Cash paid for income taxes
Non Cash Financing and Investing:
Stocks issued in settlement of notes, accounts payable, and accrued expenses	486,400	348,050
Shares issued for conversion of debt	275,000	2,434,452
Common stock issued with Debt--Debt discount	12,383	32,146
Warrants issued with Debt-Debt discount	15,517
Debt discount for beneficial conversion features		249,113
Right-of-use asset due to adoption of ASC 842	281,175
Operating lease liabilities due to adoption of ASC 842	281,175
Reclassification of accrued interest to debt	$ 66,460

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $67,864,284 at December 31, 2019. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $10,931,827 and a stockholders’ deficit of $11,701,035 at December 31, 2019. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895. We intended to use the proceeds primarily for payroll costs. During April and June 2020, we obtained the loan in the amount of $154,900 from SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 13). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers On January 1, 2018, we adopted Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, “ Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. For the year ended December 31, 2018, the revenue recognized from contracts with customers was $130,596. The impact of adoption of ASC 606 on our 2018 consolidated statement of operations was as follows: With Implementation of ASC 606 Before Implementation of ASC 606 Effect of Implementation Revenue $ 130,596 $ 126,193 $ 4,403 Costs of sales (68,777 ) (64,374 ) (4,403 ) Net effect of ASC 606 implementation $ – There was no balance sheet impact. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record shipping and handling costs incurred within revenue. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. During the year ended December 31, 2019, $2,789 of accounts receivable were written off and recorded as bad debt expense. No allowance for doubtful account is deemed to be required at December 31, 2019 and 2018. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2019 and 2018, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $23,948 and $47,757, respectively. At December 31, 2019 and 2018, the total valuation allowance for prepaid venom was $224,859 and $200,911, respectively. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2019, there were two customers that accounted for 55% and 12% of the total revenues, respectively. For the year ended December 31, 2018, there were two customers that accounted for 32% and 27% of the total revenues, respectively. As of December 31, 2019 and 2018, 100% and 84% of the accounts receivable balance are reserves due from two payment processors. Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. For periods prior to the adoption of ASC Topic 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC Topic 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented. The impact of the adoption of ASC 842 on the balance sheet was: As reported Adoption of ASC Balance December 31, 842 - increase January 1, 2018 (decrease) 2019 Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592 Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2019 and 2018, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share 31-Dec-19 31-Dec-18 Options and warrants 52,500,000 12,600,000 Convertible notes payable at fair value 11,672,780,512 4,448,128,953 Convertible notes payable 1,624,914,267 1,131,893,633 Total 13,350,194,779 5,592,622,586 Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at December 31, 2019 and 2018 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at December 31, 2019 and December 31, 2018: Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ - $ 834,457 Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047 Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2019 and 2018: Description 2019 2018 Beginning balance $ 1,468 $ 5,903 Total gain included in earnings (1) (57 ) (4,435 ) Ending balance $ 1,411 $ 1,468 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 1.55% to 1.59% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 348% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at December 31, 2019. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2019 and 2018: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days 2018 $ 1,340,026 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2019 and 2018: Description 2019 2018 Beginning balance $ 1,156,341 $ 1,925,959 Purchases and issuances 688,274 472,029 Day one loss on value of hybrid instrument (1) 926,109 2,021,041 Loss from change in fair value (1) 3,423,935 130,344 Gain on settlement - (958,581 ) Debt discount (22,344 ) - Settlement through issuance of common stock (83,268 ) - Conversion to common stock (275,000 ) (2,434,451 ) Ending balance $ 5,814,047 $ 1,156,341 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2019 and 2018, inventories were as follows: December 31, 2019 December 31, 2018 Raw Materials $ 52,183 $ 33,431 Finished Goods 8,177 1,871 Total Inventories 60,360 35,302 Less: Long-term inventory (52,183 ) - Current portion $ 8,177 $ 35,302

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (209,270 ) (205,533 ) Property and equipment, net $ 6,763 $ 10,500 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2019, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2019 and 2018 was $3,737 and $5,963, respectively.

Due to_from Officer

Due to/from Officer	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Due to/from Officer	5. DUE TO/FROM OFFICER At December 31, 2019, the balance due to our President and CEO, Rik Deitsch, is $122,812, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2019, we advanced $134,015 to and collected $5,000 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $6,330 and is included in the due to officer account. For the year ended December 31, 2019, we recorded a bad debt expense of $59,000. The Company has fully reserved receivables from companies owned by the Company’s CEO. The reserve was $564,470 and $505,470 as of December 31, 2019 and 2018, which represents a full valuation allowance for amounts owed by these Companies. At December 31, 2018, the balance due to our President and CEO, Rik Deitsch, is $186,497, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2018, we advanced $162,775 to and collected $105,900 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $7,674 and is included in the due to officer account. As of December 31, 2018, we recorded a bad debt expense of $505,470 which represents a full valuation allowance for amounts owed by these Companies.

Debts

Debts	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Debts	6. DEBTS Debts consist of the following at December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Note payable– Related Party (Net of discount of $0 and $2,400, respectively) (1) $ 14,400 $ 12,000 Notes payable – Unrelated third parties (Net of discount of $8,921 and $17,870, respectively) (2) 1,385,163 1,469,690 Convertible notes payable – Unrelated third parties (Net of discount of $17,370 and $29,371, respectively) (3) 872,256 751,955 Convertible notes payable, at fair value (Net of discount of $22,344 and $0, respectively) (4) 5,814,047 1,156,341 Other advances from an unrelated third party (5) 175,000 - Ending balances 8,260,866 3,389,986 Less: Long-term portion-Notes payable-Unrelated third parties $ (-) $ (51,410 ) Less: Long-term portion-Convertible Notes payable-Unrelated third parties (907,912 ) - Current portion $ 7,352,954 $ 3,338,576 F-14 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2019 and 2018, we owed this director accrued interest of $159,555 and $141,808. The interest expense for the years ended December 31, 2019 and 2018 was $17,747 and $15,772. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At December 31, 2019 and 2018, the principal balance of the loan is $14,400 and $12,000, net of debt discount of $0 and $2,400, respectively. The Note was settled in June 2020. (2) At December 31, 2019 and 2018, the balance of $1,385,163 and $1,469,690 net of discount of $8,921 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 13) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2019 and 2018, the accrued interest is $3,755 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the outstanding principal balance is $50,000 and accrued interest is $49,967 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2019 and 2018, the outstanding principal balance is $50,000 and accrued interest is $43,166 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018 (See Note 7). The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount for the years ended December 31, 2019 and 2018 was $3,616 and $329, respectively. During September 2019, the Notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895(See Note 7) and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the year ended December 31, 2019 was $1,474 and debt discount at December 31, 2019 is $4,421. The Note is in default and negotiation of settlement. At December 31, 2019 and 2018, the principal balance is $333,543 and $282,983, and the accrued interest is $25,127 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At December 31, 2019 and 2018, the principal balance outstanding is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the accrued interest is $39,466 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the accrued interest is $3,212 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 and $42,698 during 2018 and 2019, respectively. At December 31, 2019 and 2018, the principal balance is $92,728 and $135,426. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2019. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 7). As of December 31, 2018, the note was repaid in full. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the years ended 2019 and 2018 was $7,500 and $4,000, respectively. Repayments of $1,500, $7,000 and $5,000 have been made during 2017, 2018 and 2019, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2019 and 2018, the principal balance of the note is $30,000 and $27,500, net of debt discount of $4,500 and $6,000, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment (See Note 7). The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount for a total of $18,678 have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the year ended December 31, 2019 and 2018 was $8,254 and $4,127, respectively, for the restated Note in November 2018. As of December 31, 2019 and 2018, the amount due is $60,000 and $61,746, net of discount of $0 and $8,254, respectively. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 13). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in May 2018(See Note 7). During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At December 31, 2019 and 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. In September 2018, 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600. At December 31, 2019 and 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. ● In December 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in one year from the execution and funding of the note. During August 2018, the Note holder sold the debt of $60,000 to a non-related party. The subsequent note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 7). As a result of the settlement of the note, the debt discount has been fully amortized as of December 31, 2018. At December 31, 2018, the note was repaid in full. (3) At December 31, 2019 and 2018, the balance of $872,256 and $751,955 net of discount of $17,370 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and was due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019 and 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of December 31, 2019 and 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 13). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. In April 2018, 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 (See Note 7). At December 31, 2019 and 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock (See Note 7). The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. Amortization for the year ended December 31, 2018 was $290,184. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 is $589,829. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share in 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in August and October 2020 and are currently in default and in negotiation of settlement. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The Note is in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stocks as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019(see Note 7). Amortization for the year ended December 31, 2019 was $55,222. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 is $736,180. $574,550 of the above mentioned convertible notes payable to 16 of the unrelated third parties are in default and in negotiation of settlement. Two of the above mentioned convertible notes payable for a total of $19,500 was settled in full in March and April 2021(See Note 13). (4) At December 31, 2019 and 2018, the balance of $5,814,047 and $1,156,341 net of discount of $22,344 and $0, respectively, consisted of the following convertible loans: ● During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 6(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. ● On March 31, 2017, we issued a convertible debenture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). ● On July 18, 2017, we issued a convertible debenture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Deficit	7 . STOCKHOLDERS’ DEFICIT Authorized Shares On March 7, 2018, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 2,000,000,000 to 8,000,000,000. Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 shares of stock designated “preferred shares”, issuable from time to time in one or more series and authorize the Board of Directors to fix the number of shares constituting any such series, and to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, right and terms of redemption (including sinking fund provisions), the redemption price or prices and the liquidation preference of any wholly unissued series of such preferred shares, and the number of shares constituting any such series. Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 shares of Series A Preferred Stock (“Series A Preferred”). Terms of the Series A Preferred include the following: 1. The Series A Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred will have the same record and payment date and terms as the dividend payable on the common stock. 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series A Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $0.133 in cash per share before any distribution is made on any shares of the Company’s common stock. If upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the application of all amounts available for payments with respect to Series A Preferred would not result in payment in full of Series A Preferred, the holders shall share equally and ratably in any distribution of assets of the Company in proportion to the full liquidation preference to which each is entitled. 4. The Series A Preferred does not have any redemption rights. Common Stock Issued with Indebtedness In January and February 2018, in connection with four notes payable, we issued a total of 4,250,000 shares of our restricted common stock with a fair value of $9,887 (See Note 6). In April 2018, in connection with a note payable, we issued a total of 5,000,000 shares of our restricted common stock with a fair value of $8,678 (See Note 6). In August 2018, in connection with a note payable, we issued a total of 5,000,000 shares of our restricted common stock with a fair value of $3,800 (See Note 6). In October through December, 2018, in connection with a note payable, we issued a total of 25,500,000 shares of our restricted common stock with a fair value of $9,781 (See Note 6). In May 2019, in connection with amendment of two convertible notes payable, we issued a total of 6,000,001 shares of our common stock with a fair value of $1,800 (See Note 6). In June 2019, in connection with issuance of a convertible notes payable, we issued a total of 16,000,000 shares of our common stock with a fair value of $4,688 (See Note 6). In September 2019, in connection with amendment of a promissory notes payable, we issued 20,000,000 shares of our common stock with a fair value of $5,895 (See Note 6). Common Stock Issued for Conversion of Convertible Debt During February 2018, a Note holder made conversions of a total of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of the principal balance of $30,854 of an $80,000 Note originated in March 2017 (See Note 6). During February 2018, a Note holder received 109,876,500 shares of our restricted common stock with a fair value of $462,625 upon conversion of $29,646 of an $84,971 Note originated in June 2017 (See Note 6). During February 2018, a Note holder received 45,000,000 of our restricted common stock with a fair value of $247,500 upon conversion of the remaining balance of $78,943 of $90,000 Notes originated in May and October 2017 (See Note 6). During April and May 2018, a Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 assigned and purchased from a Note originated in March 2017 (See Note 6). During May and June 2018, a Note holder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in satisfaction of the balance of $70,000 of a $156,000 Note assigned and purchased from a Note originated in July 2017 (See Note 6). During May 2018, a Note holder received a total of 228,000,000 shares of our restricted common stock with a fair value of $319,200 in satisfaction of the remaining principal balance of $54,800 assigned and purchased from a Note originated in June 2016 (See Note 6). During June 2018, a Note holder made a conversion of 150,000,000 shares of our restricted common stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 of $33,000 Notes originated in May 2017 (See Note 6). During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the principal balance of $34,060 and accrued interest of $6,476 assigned and purchased from a Note originated in May 2017 (See Note 6). During July through September 2018, a Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full from a Note originated in February 2018(See Note 6). During September 2018, a Note holder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full from a Note originated in February 2018 (See Note 6). During August 2018, a Note holder received a total of 300,000,000 shares of our restricted common stock with a fair value of $300,000 in satisfaction of the principal balance of $72,000 with accrued interest in full for a Note originated in July 2016 (See Note 6). During May and June 2019, the Note holder made conversions of a total of 750,000,000 shares of stock for a fair value of $275,000 satisfying the principal balance of $100,000 of a Note originated in February 2019 in the amount of up to $1,000,000.(See Note 6). Number of Fair Value of Date shares converted Debt Converted 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000 Common Stock Issued for Settlement of Accounts Payable, Accrued expense and Debt During May 2018, a Note holder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500 from a Note originated in September 2017 in full. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 6). During August 2018, a Note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 originated in December 2017 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 6). During August 2018, the Company issued a total of 2,800,000 shares of the Company’s restricted common stock to settle the outstanding fees of $4,200 with a fair value of $2,800. We recorded a gain on settlement of accounts payable in other expense for $1,400. During January 2019, in connection with the settlement of a default penalty of debt of $110,000 originated in December 2016, we issued a total of 81,000,000 shares of our restricted common stock with a fair value of $32,400 to the Note holder (See Note 6). We had an accrual of $32,400 to account for the cost of the shares at December 31, 2018. During December 2019, six convertible promissory Notes for a total of $87,100 (See Note 6(3)), one Note of $19,984 assigned from the convertible Note of $29,381 (See Note 6(4)), and the accrued consulting fees of $39,000, were settled with 800,000,000 shares of common stocks. The shares were valued at fair value of $454,000. We recorded a loss on settlement in other expense for $244,632. Common Stock Issued for Debt Modification and Penalty During February and July, 2018, in connection with the settlement of a default penalty of debt, we issued a total of 105,157,409 shares of our restricted common stock with a fair value of $147,220 to the Note holder (See Note 6). During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment of the promissory note of $50,000 originated in October 2017.The shares were valued at fair value of $1,700. During April through December, 2018, we issued a total of 33,625,000 restricted shares to 14 Note holders due to the default on repayment of the promissory notes. The shares were valued at fair value of $25,615. During May and June 2019, we issued a total of 3,500,000 restricted shares to three Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $1,050. During July through September 2019, we issued a total of 18,500,000 restricted shares to five Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $6,650. Common Stock Issued for Services During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The shares were valued at $0.0012 per share. The Company recorded an equity compensation charge of $50,000 and $70,000 during the years ended December 31, 2019 and 2018. During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. The Company recorded an equity compensation charge of $21,500 during the year ended December 31, 2019. The remaining unrecognized compensation cost of $8,500 will be recognized by the Company over the remaining service period. Warrants Issued with Debt The Company granted the following warrants at an exercise price of $0.001 per share in connection with issuances of convertible notes payable of $70,000 in February 2019 and amendment of convertible notes payable of $22,000 in December 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 Beneficial Conversion Features During 2018, the Company has recorded a beneficial conversion feature in the amount of $249,113 as additional paid-in capital due to the difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes (See Note 6).

Stock Warrants

Stock Warrants	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Warrants	8. STOCK WARRANTS Common Stock Warrants During March, 2013, the Company issued a total of 65,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expired on March 22, 2018. On September 3, 2013 and September 12, 2013, the Company issued 500,000 and 375,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 and $0.01 per share in connection with issuances of convertible notes payable to Coventry. The warrants expired on September 3, 2018 and September, 12, 2018, respectively. On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $539 and $977 using the Black-Scholes method on December 31, 2019 and 2018. The warrants expired on March 30, 2020. On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $872 and $491 using the Black-Scholes method at December 31, 2019 and 2018. The warrants expired on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 4, 2019. During April 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 9, 2019. The Company granted the following warrants at an exercise price of $0.001 per share in connection with issuances of three convertible notes payable of $70,000 in February 2019 and amendment of one convertible notes payable of $22,000 in December 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2019 and 2018: Number Of shares Weighted average exercise price Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Expired (940,000 ) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 The following table summarizes information about fixed-price warrants outstanding as of December 31, 2019 and 2018 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.026 At December 31, 2019, the aggregate intrinsic value of all warrants outstanding and expected to vest was $0. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0005, closing stock price of our restricted common stock on December 31, 2019. There were no in-the-money warrants at December 31, 2019.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2019 and 2018, (computed by the following blended rate), are approximately as follows. 2019 2018 Tax Rate Reconciliation: Federal tax rate 21.00 % 21.00 % Add: State taxes 5.50 % 5.50 % Permanent difference -1.15 % -1.15 % Valuation allowance and change in federal tax rate -25.35 % -25.35 % Tax rate - - December 31, 2019 2018 Computed “expected” tax expense (benefit) - Federal $ (1,384,203 ) (793,340 ) Computed “expected” tax expense (benefit) - State (286,398 ) (164,145 ) Permanent differences 1,313,998 571,235 Change in federal tax rate - 4,134,665 Change in valuation allowance 356,603 (3,748,415 ) Provision for income taxes $ - $ - 2019 2018 Net deferred income tax assets: Reserve for prepaid inventory $ 18,174 $ 12,104 Accrued salary 316,659 296,834 Reserve for receivables from officer 14,954 - Net operating loss carryforwards 9,398,889 9,083,135 Valuation allowance (9,748,676 ) (9,392,073 ) Net deferred income tax asset $ - $ - Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets. The valuation allowances increased by $356,603 for the year ended December 31, 2019 and decreased by $3,748,415 for the year ended December 31, 2018. As of December 31, 2019, the Company has net operating loss of approximately $37.1 million as of December 31, 2019, of which $1.7 million were incurred after December 31, 2017 that are available to offset future taxable income with no expiration date. The remaining approximately $35.4 million of net operating loss of expired between 2030 and 2037. In December 2017, the United States Government passed new tax legislation that, among other provisions, lowered the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income the Company may have, the legislation affects the way the Company can use and carryforward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on the balance sheet. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no net impact on the balance sheet. However, when the Company becomes profitable, the Company will receive a reduced benefit from such deferred tax assets. The Company’s 2017 through 2019 tax returns are subject to examination by the Internal Revenue Services and various state authorities.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses	10. ACCRUED EXPENSES Accrued expenses consisted of the following: December 31, 2019 2018 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 35,000 347,400 Accrued payroll taxes 167,906 120,182 Accrued interest 231,186 180,509 Accrued others 16,905 22,208 Total $ 612,547 $ 831,849

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	11. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: December 31, 2019 December 31, 2018 Supplier advances for future purchases $ 224,859 $ 200,911 Reserve for supplier advances (224,859 ) (200,911 ) Net supplier advances - - Prepaid professional fees 8,650 13,000 Deferred stock compensation 8,500 50,000 Total $ 17,150 $ 63,000 We performed an evaluation of our inventory and related accounts at December 31, 2019 and 2018, and increased the reserve on supplier advances for future venom purchases by $23,948 and $47,757, respectively. At December 31, 2019 and 2018, the total valuation allowance for prepaid venom is $224,859 and $200,911, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into our current three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. The lease is currently month-to-month, thus classified as short-term and not reported on the balance sheet under ASC 842. ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. December 31, 2019 Lease cost Operating lease cost $ 89,021 Short-term lease cost 45,026 Total lease cost $ 134,047 Balance sheet information Operating ROU Assets $ 207,530 Operating lease obligations, current portion 73,278 Operating lease obligations, non-current portion 143,322 Total operating lease obligations $ 216,600 Weighted average remaining lease term (in years) – operating leases 2.67 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the year ended December 31, 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 79,950 Future minimum payments under these lease agreements are as follows: December 31, Total 2020 $ 87,991 2021 91,379 2022 62,274 Total future lease payments $ 241,644 Less imputed interest 25,044 Total $ 216,600 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of December 31, 2019. We have accrued the $142,500 in accrued expense and equity compensation. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of December 31, 2019, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. On June 1, 2015, ReceptoPharm entered into a settlement agreement with Patricia Meding, a former officer and shareholder of ReceptoPharm. The settlement relates to a lawsuit filed by Ms. Meding against ReceptoPharm (Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06, New York Supreme Court, Queens County) in which she claimed to own certain shares of ReceptoPharm stock and claimed to be owed amounts on a series of promissory notes allegedly executed in 2001 and 2002. The settlement agreement executed on June 1, 2015 provides that ReceptoPharm will pay Ms. Meding a total of $360,000 over 35 months. The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter. To date, ReceptoPharm has made all monthly payments due under the agreement. In the event of default on any of the payments due under the settlement agreement, the settlement amount would increase by an additional $200,000. As of December 31, 2019, all payments were made and the settlement was concluded. We have recorded $200,000 in gain on settlement of debt on the consolidated statements of operations upon payments in full in April 2018. Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. On June 24, 2021, the parties entered into a confidential settlement agreement of the lawsuit. Nutra Pharma has fully performed under the settlement and considers the case fully resolved. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023. The lawsuit was settled on February 15, 2019 for $104,000 with scheduled payments. The repayments were made in full as of November 2020 (See Note 6). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At December 31, 2019, we owed principal balance of $91,156 and accrued interest of $29,948 (See Note 6) if the defenses and our new claims are deemed to be of no merit. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On March 24, 2021, the Court entered an order granting the Motion for Extension of Time and modified the briefing schedule as follows: Plaintiffs’ Motion was due on or before April 9, 2021, the Defendants’ Response was due on or before May 7, 2021, and the Plaintiffs’ Reply was due on or before May 21, 2021. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	13. SUBSEQUENT EVENTS Convertible Notes Payable During August 2020, the convertible promissory notes of $38,500 was amended with additional original issuance discount of $7,550 due February 2021. During October 2020, the convertible promissory note of $16,500 was amended with additional original issuance discount (OID) of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The gross proceeds of the notes were allocated to debt and warrants issued on a relative fair value basis. The debt discounts associated with the warrants and OID for $29,481 and $9,200, respectively, are amortized over the life of the notes. Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration August, 2020 92,100,000 $ 20,848 August, 2021 October, 2020 39,930,000 $ 8,633 October, 2022 Pursuant to the Note agreement in the amount up to $1,000,000 signed in February 2019, the proceeds in the amount of $372,374 have been funded as of December 31, 2019. Proceeds in the amount of $122,362 have been funded subsequent to December 31, 2019. During January 2020 through February 2020, the Note holder received a total of 500,000,000 shares of our restricted common stock in satisfaction the $175,000 of the Note with a fair value of $425,000. During February through June 2021, the Note holder received a total of 237,850,000 shares of our restricted common stock in satisfaction the $118,925 of the Note with a fair value of $2,328,149. The remaining balance of $100,810 is due March 2023. Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 During January and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $68,750 with original issuance discount of $6,250. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The Notes were due in January and March 2021. The Notes are in default and negotiation of settlement. During February and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $22,000 with original issuance discount of $2,000. The notes were due six months from the execution and funding of the notes. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0003. The Notes are in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The Note is in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for a $22,000 with original issuance discount of $2,000. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The note is due August 2021. During July 2020, we issued a convertible promissory note to an unrelated third party for $20,900 with original issuance discount of $1,900. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00052. The note was due January 2021. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The note was due February 2021. The Note is in default and negotiation of settlement. During October and November 2020, we issued convertible promissory notes to 3 unrelated third parties for $208,800 with original issuance discount of $19,800. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.00022 to $0.0005 per share. The notes were due in April and May 2021. The Notes are in default and negotiation of settlement. During November 2020, we issued a convertible promissory note to an unrelated third party for $139,150 with original issuance discount of $12,650. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00055. The note is due November 2021. During November and December 2020, we issued two convertible promissory notes to unrelated third parties for a total of $57,500 with original issuance discount of $7,500. The notes are due one year from the execution and funding of the notes. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0008. In connection with the issuance of convertible notes, the Company granted the 71,875,000 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance. The warrants are valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The gross proceeds of the notes were allocated to debt and warrants issued on a relative fair value basis. The debt discounts associated with the warrants and OID for $30,417 and $7,500, respectively, are amortized over the life of the notes. During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note restated in January 2019 to a third party. The third party subsequently received a total of 100,000,000 shares of our restricted common stock in satisfaction the $20,000 of the Note with a fair value of $140,000. At December 31, 2020, the balance of $55,900 remains outstanding. The note was due January 2021. The Note is in default and negotiation of settlement. During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $717,667 with original issuance discount of $93,609. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0003 to $0.002 per share. The notes are due one year from the execution and funding of the notes. During the second quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $265,650 with original issuance discount of $34,650. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0008 to $0.002 per share. The notes are due one year from the execution and funding of the notes. PPP Loan During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. Economic Injury Disaster Loan During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $154,900, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due twelve months from the date of the SBA Loan Agreement in the amount of $731. The balance of principal and interest is payable over a 360 month period from the date of the SBA Loan Agreement. In connection therewith, the Company received a $5,000 advance, which does not have to be repaid. The SBA requires that the Company collateralize the loan to the maximum extent up to the loan amount. If business fixed assets do not “fully secure” the loan the lender may include trading assets (using 10% of current book value for the calculation), and must take available equity in the personal real estate (residential and investment) of the principals as collateral. Restatement of Promissory Notes During January 2020, the Note of $60,000 with original issuance discount of $10,000 amended in November 2018 and the Note of $88,225 plus accrued interest at a rate of 2.5% monthly to an unrelated third party were combined and restated. The restated principal balance was $148,225 that carries interest at a rate of 2.0% monthly due July 2020. During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. During February 2021, we issued 29,072,500 shares of common stock to satisfy the accrued interest of $23,258 with fair value of $343,056. The settlement of accrued interest resulted in a loss on settlement of debt in other income for $319,798. The principal balance of $166,926 was further restated. The restated balance is $183,619 with an original issuance discount of $16,693 and is due August 2021. Settlement of Convertible Promissory Notes During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on December 31, 2019 was $511,319. During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. During October 2020, the Note holder sold the remaining debt of $467,319 and accrued interest of $166,168 for $250,000 to a non-related party. Number of Fair Value of Date shares converted Debt Converted 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691 During March 2021, in connection with this settlement of the $6,000 of the Note of $11,000 originated in November 2018, we issued 11,000,000 shares of common stocks in satisfaction of $6,000 of the Note with a fair value of $104,500 and made a repayment of $5,000 in cash. The settlement resulted in a loss on settlement of debt in other expense for $98,500. During April 2021, in connection with this settlement of the remaining balance of $8,500 of the Note of $12,000 originated in December 2018, we issued 2,000,000 shares of common stocks in satisfaction of $4,000 of the Note with a fair value of $15,200 and made a repayment of $4,500 in cash. The settlement resulted in a loss on settlement of debt in other expense for $11,200. Settlement and Restatement of Promissory Notes During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. Settlement of a Related-Party Note During June 2020, the Note of $14,400 with original issuance discount of $2,400 to a related party amended in December 2018 was settled with cash payment of $14,400 and 5,000,000 shares of common stocks. The shares were valued at fair value of $3,000. Common Stock Issued for Default Payments During January 2020, we issued a total of 75,000,000 restricted shares to a Note holder due to the default on repayments of the convertible promissory note of a total of $148,225 amended in August and November 2018. The shares were valued at fair value of $45,000. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500. Convertible notes receivable On March 10, 2021, we purchased a convertible note from an unrelated third party for a total of $26,950 with original issuance discount of $2,450. The note is convertible into common shares for $0.01 per common share and mature on March 10, 2022.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Organization	Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ®
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June, 2011. All intercompany transactions and balances have been eliminated in consolidation.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Liquidity and Going Concern	Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $67,864,284 at December 31, 2019. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $10,931,827 and a stockholders’ deficit of $11,701,035 at December 31, 2019.
Impact of COVID-19 on our Operations	Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895. We intended to use the proceeds primarily for payroll costs. During April and June 2020, we obtained the loan in the amount of $154,900 from SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 13). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine.
Use of Estimates	Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers	Revenue from Contracts with Customers On January 1, 2018, we adopted Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, “ Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. For the year ended December 31, 2018, the revenue recognized from contracts with customers was $130,596. The impact of adoption of ASC 606 on our 2018 consolidated statement of operations was as follows: With Implementation of ASC 606 Before Implementation of ASC 606 Effect of Implementation Revenue $ 130,596 $ 126,193 $ 4,403 Costs of sales (68,777 ) (64,374 ) (4,403 ) Net effect of ASC 606 implementation $ – There was no balance sheet impact.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record shipping and handling costs incurred within revenue.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. During the year ended December 31, 2019, $2,789 of accounts receivable were written off and recorded as bad debt expense. No allowance for doubtful account is deemed to be required at December 31, 2019 and 2018.
Inventories	Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2019 and 2018, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $23,948 and $47,757, respectively. At December 31, 2019 and 2018, the total valuation allowance for prepaid venom was $224,859 and $200,911, respectively.
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2019, there were two customers that accounted for 55% and 12% of the total revenues, respectively. For the year ended December 31, 2018, there were two customers that accounted for 32% and 27% of the total revenues, respectively. As of December 31, 2019 and 2018, 100% and 84% of the accounts receivable balance are reserves due from two payment processors.
Operating Lease Right-of-Use Asset and Liability	Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. For periods prior to the adoption of ASC Topic 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC Topic 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented. The impact of the adoption of ASC 842 on the balance sheet was: As reported Adoption of ASC Balance December 31, 842 - increase January 1, 2018 (decrease) 2019 Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592
Derivative Financial Instruments	Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt	Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
The Fair Value Measurement Option	The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging
Derivative Accounting for Convertible Debt and Options and Warrants	Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
Long-Lived Assets	Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.
Income Taxes	Income Taxes We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2019 and 2018, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation
Net Loss Per Share	Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share 31-Dec-19 31-Dec-18 Options and warrants 52,500,000 12,600,000 Convertible notes payable at fair value 11,672,780,512 4,448,128,953 Convertible notes payable 1,624,914,267 1,131,893,633 Total 13,350,194,779 5,592,622,586
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share	As of December 31, 2019 and 2018, the following items were not included in dilutive loss as the effect is anti-dilutive: 31-Dec-19 31-Dec-18 Options and warrants 52,500,000 12,600,000 Convertible notes payable at fair value 11,672,780,512 4,448,128,953 Convertible notes payable 1,624,914,267 1,131,893,633 Total 13,350,194,779 5,592,622,586
ASC 606 [Member]
Schedule of Impact of Adoption of ASC	The impact of adoption of ASC 606 on our 2018 consolidated statement of operations was as follows: With Implementation of ASC 606 Before Implementation of ASC 606 Effect of Implementation Revenue $ 130,596 $ 126,193 $ 4,403 Costs of sales (68,777 ) (64,374 ) (4,403 ) Net effect of ASC 606 implementation $ –
ASC 842 [Member]
Schedule of Impact of Adoption of ASC	The impact of the adoption of ASC 842 on the balance sheet was: As reported Adoption of ASC Balance December 31, 842 - increase January 1, 2018 (decrease) 2019 Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Summary of Financial Instruments Measured at Fair Value	The following table summarizes our financial instruments measured at fair value at December 31, 2019 and December 31, 2018: Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ - $ 834,457 Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047 Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2019 and 2018: Description 2019 2018 Beginning balance $ 1,468 $ 5,903 Total gain included in earnings (1) (57 ) (4,435 ) Ending balance $ 1,411 $ 1,468 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
Summary of Assumptions and the Significant Terms	The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2019 and 2018: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days 2018 $ 1,340,026 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days
Convertible Notes Payable [Member]
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2019 and 2018: Description 2019 2018 Beginning balance $ 1,156,341 $ 1,925,959 Purchases and issuances 688,274 472,029 Day one loss on value of hybrid instrument (1) 926,109 2,021,041 Loss from change in fair value (1) 3,423,935 130,344 Gain on settlement - (958,581 ) Debt discount (22,344 ) - Settlement through issuance of common stock (83,268 ) - Conversion to common stock (275,000 ) (2,434,451 ) Ending balance $ 5,814,047 $ 1,156,341 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	At December 31, 2019 and 2018, inventories were as follows: December 31, 2019 December 31, 2018 Raw Materials $ 52,183 $ 33,431 Finished Goods 8,177 1,871 Total Inventories 60,360 35,302 Less: Long-term inventory (52,183 ) - Current portion $ 8,177 $ 35,302

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following at December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (209,270 ) (205,533 ) Property and equipment, net $ 6,763 $ 10,500

Debts (Tables)

Debts (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Debt	Debts consist of the following at December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Note payable– Related Party (Net of discount of $0 and $2,400, respectively) (1) $ 14,400 $ 12,000 Notes payable – Unrelated third parties (Net of discount of $8,921 and $17,870, respectively) (2) 1,385,163 1,469,690 Convertible notes payable – Unrelated third parties (Net of discount of $17,370 and $29,371, respectively) (3) 872,256 751,955 Convertible notes payable, at fair value (Net of discount of $22,344 and $0, respectively) (4) 5,814,047 1,156,341 Other advances from an unrelated third party (5) 175,000 - Ending balances 8,260,866 3,389,986 Less: Long-term portion-Notes payable-Unrelated third parties $ (-) $ (51,410 ) Less: Long-term portion-Convertible Notes payable-Unrelated third parties (907,912 ) - Current portion $ 7,352,954 $ 3,338,576 F-14 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2019 and 2018, we owed this director accrued interest of $159,555 and $141,808. The interest expense for the years ended December 31, 2019 and 2018 was $17,747 and $15,772. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At December 31, 2019 and 2018, the principal balance of the loan is $14,400 and $12,000, net of debt discount of $0 and $2,400, respectively. The Note was settled in June 2020. (2) At December 31, 2019 and 2018, the balance of $1,385,163 and $1,469,690 net of discount of $8,921 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 13) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2019 and 2018, the accrued interest is $3,755 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the outstanding principal balance is $50,000 and accrued interest is $49,967 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2019 and 2018, the outstanding principal balance is $50,000 and accrued interest is $43,166 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018 (See Note 7). The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount for the years ended December 31, 2019 and 2018 was $3,616 and $329, respectively. During September 2019, the Notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895(See Note 7) and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the year ended December 31, 2019 was $1,474 and debt discount at December 31, 2019 is $4,421. The Note is in default and negotiation of settlement. At December 31, 2019 and 2018, the principal balance is $333,543 and $282,983, and the accrued interest is $25,127 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At December 31, 2019 and 2018, the principal balance outstanding is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the accrued interest is $39,466 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the accrued interest is $3,212 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 and $42,698 during 2018 and 2019, respectively. At December 31, 2019 and 2018, the principal balance is $92,728 and $135,426. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2019. The note is in default and in negotiation of settlement. At December 31, 2019 and 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted common stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500. We recorded a loss on settlement of debt in other expense for $201,250 (See Note 7). As of December 31, 2018, the note was repaid in full. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the years ended 2019 and 2018 was $7,500 and $4,000, respectively. Repayments of $1,500, $7,000 and $5,000 have been made during 2017, 2018 and 2019, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2019 and 2018, the principal balance of the note is $30,000 and $27,500, net of debt discount of $4,500 and $6,000, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment (See Note 7). The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount for a total of $18,678 have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the year ended December 31, 2019 and 2018 was $8,254 and $4,127, respectively, for the restated Note in November 2018. As of December 31, 2019 and 2018, the amount due is $60,000 and $61,746, net of discount of $0 and $8,254, respectively. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 13). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in May 2018(See Note 7). During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At December 31, 2019 and 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. In September 2018, 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600. At December 31, 2019 and 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. ● In December 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in one year from the execution and funding of the note. During August 2018, the Note holder sold the debt of $60,000 to a non-related party. The subsequent note holder received a total of 145,000,000 shares of our restricted common stock with a fair value of $101,500 in satisfaction of the Note of $60,000 in full. We recorded a loss on settlement of debt in other expense for $41,500 (See Note 7). As a result of the settlement of the note, the debt discount has been fully amortized as of December 31, 2018. At December 31, 2018, the note was repaid in full. (3) At December 31, 2019 and 2018, the balance of $872,256 and $751,955 net of discount of $17,370 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and was due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019 and 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of December 31, 2019 and 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 13). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. In April 2018, 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 (See Note 7). At December 31, 2019 and 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock (See Note 7). The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. Amortization for the year ended December 31, 2018 was $290,184. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 is $589,829. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share in 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in August and October 2020 and are currently in default and in negotiation of settlement. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The Note is in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stocks as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019(see Note 7). Amortization for the year ended December 31, 2019 was $55,222. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 is $736,180. $574,550 of the above mentioned convertible notes payable to 16 of the unrelated third parties are in default and in negotiation of settlement. Two of the above mentioned convertible notes payable for a total of $19,500 was settled in full in March and April 2021(See Note 13). (4) At December 31, 2019 and 2018, the balance of $5,814,047 and $1,156,341 net of discount of $22,344 and $0, respectively, consisted of the following convertible loans: ● During December 2015, Mr. Deitsch, assigned $80,000 of his outstanding loan to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note (See Note 6(2)). The note carries interest at 8% and was due on June 27, 2018, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of Common Stock at fifty-five percent (55%) of lowest closing bid prices of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of our restricted common stock satisfying the principal balance of $55,325 with a fair value of $225,143. During February 2018, the Note holder made conversions of a total of 109,876,500 shares of our restricted common stock with a fair value of $462,625 in satisfaction of the remaining principal balance of $29,646 in full. ● On March 31, 2017, we issued a convertible debenture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and was due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted common stock with a fair value of $294,885 in satisfaction of a portion of the Note in the amount of $30,854 (See Note 7). The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our restricted common stock with a fair value of $145,161 in satisfaction of the remaining principal balance of $49,146 and accrued interest in full (See Note 7). ● On July 18, 2017, we issued a convertible debenture in the amount of $150,000 to Coventry. The note carries interest at 8% and was due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note into shares of Common Stock at a fifty-five percent (55%) of the of the lowest closing bid price of our restricted common stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted common stock with a fair value of $200,475 in partial satisfaction of the note in the amount of $70,000 (See Note 7). During July through September 2018, the Note holder made conversions of a total of 206,988,570 shares of our restricted common stock with a fair value of $176,655 in satisfaction of the remaining principal balance $86,000 and accrued interest in full (See Note 7). ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000
Schedule of Warrants Issued with Debt	Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020

Stock Warrants (Tables)

Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Warrants Issued	The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020
Summary of Warrants Outstanding	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2019 and 2018: Number Of shares Weighted average exercise price Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Expired (940,000 ) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028
Summary of Fixed Price Warrants Outstanding	The following table summarizes information about fixed-price warrants outstanding as of December 31, 2019 and 2018 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.026

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2019 and 2018, (computed by the following blended rate), are approximately as follows. 2019 2018 Tax Rate Reconciliation: Federal tax rate 21.00 % 21.00 % Add: State taxes 5.50 % 5.50 % Permanent difference -1.15 % -1.15 % Valuation allowance and change in federal tax rate -25.35 % -25.35 % Tax rate - -
Schedule of Income Tax Expense	December 31, 2019 2018 Computed “expected” tax expense (benefit) - Federal $ (1,384,203 ) (793,340 ) Computed “expected” tax expense (benefit) - State (286,398 ) (164,145 ) Permanent differences 1,313,998 571,235 Change in federal tax rate - 4,134,665 Change in valuation allowance 356,603 (3,748,415 ) Provision for income taxes $ - $ -
Schedule of Deferred Income Tax Assets	2019 2018 Net deferred income tax assets: Reserve for prepaid inventory $ 18,174 $ 12,104 Accrued salary 316,659 296,834 Reserve for receivables from officer 14,954 - Net operating loss carryforwards 9,398,889 9,083,135 Valuation allowance (9,748,676 ) (9,392,073 ) Net deferred income tax asset $ - $ -

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: December 31, 2019 2018 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 35,000 347,400 Accrued payroll taxes 167,906 120,182 Accrued interest 231,186 180,509 Accrued others 16,905 22,208 Total $ 612,547 $ 831,849

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses	Prepaid expenses and other current assets consist of the following: December 31, 2019 December 31, 2018 Supplier advances for future purchases $ 224,859 $ 200,911 Reserve for supplier advances (224,859 ) (200,911 ) Net supplier advances - - Prepaid professional fees 8,650 13,000 Deferred stock compensation 8,500 50,000 Total $ 17,150 $ 63,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost and Balance Sheet Information	December 31, 2019 Lease cost Operating lease cost $ 89,021 Short-term lease cost 45,026 Total lease cost $ 134,047 Balance sheet information Operating ROU Assets $ 207,530 Operating lease obligations, current portion 73,278 Operating lease obligations, non-current portion 143,322 Total operating lease obligations $ 216,600 Weighted average remaining lease term (in years) – operating leases 2.67 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the year ended December 31, 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 79,950
Schedule of Future Minimum Payments Under Lease Agreements	Future minimum payments under these lease agreements are as follows: December 31, Total 2020 $ 87,991 2021 91,379 2022 62,274 Total future lease payments $ 241,644 Less imputed interest 25,044 Total $ 216,600

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000
Convertible Notes Payable [Member]
Summary of Warrants Issuance	Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration August, 2020 92,100,000 $ 20,848 August, 2021 October, 2020 39,930,000 $ 8,633 October, 2022
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340
Settlement of Convertible Promissory Notes [Member]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated deficit			$ (67,864,284)	$ (61,272,842)
Working capital deficit			(10,931,827)
Stockholders' deficit			(11,701,035)	(5,936,593)	$ (5,410,194)
Net sales			104,393	130,596
Accounts receivable written off			2,789
Allowance for doubtful account
Change in reserve for supplier advances for purchases			23,948	47,757
Inventory adjustments			$ 224,859	$ 200,911
Minimum [Member]
Property and equipment estimated useful lives			3 years
Maximum [Member]
Property and equipment estimated useful lives			7 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration risk, percentage			55.00%	32.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration risk, percentage			12.00%	27.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration risk, percentage			100.00%	84.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration risk, percentage			100.00%	84.00%
ASC 606 [Member]
Net sales				$ 4,403
Subsequent Event [Member] | PPP [Member]
Proceeds form loan	$ 64,895	$ 154,900

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Impact of Adoption of ASC (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 02, 2019
Revenue	$ 104,393	$ 130,596
Operating lease right-of-assets	207,530		$ 281,175
Total assets	339,832	141,417	422,592
Operating lease liabilities, current portion	73,278		64,573
Operating lease liabilities, net of current portion	143,322		216,602
Total liabilities	12,040,867	6,078,010	6,359,185
Total liabilities and stockholders' equity	$ 339,832	141,417	$ 422,592
With ASC 606 [Member]
Revenue		130,596
Cost of sales		(68,777)
Before ASC 606 [Member]
Revenue		126,193
Cost of sales		(64,374)
ASC 606 [Member]
Revenue		4,403
Cost of sales		(4,403)
Net effect of ASC 606 implementation
Adoption of ASC 842 - Increase (Decrease) [Member]
Operating lease right-of-assets		281,175
Total assets		281,175
Operating lease liabilities, current portion		64,573
Operating lease liabilities, net of current portion		216,602
Total liabilities		281,175
Total liabilities and stockholders' equity		$ 281,175

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities excluded from computation of earnings per share	13,350,194,779	5,592,622,586
Option and Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	52,500,000	12,600,000
Convertible Notes Payable [Member]
Antidilutive securities excluded from computation of earnings per share	11,672,780,512	3,260,602,785
Convertible Notes Payable Fair Value [Member]
Antidilutive securities excluded from computation of earnings per share	1,624,914,267	1,131,893,633

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	Dec. 31, 2019
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants outstanding, measurement input	1.55
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants outstanding, measurement input	1.59
Measurement Input, Price Volatility [Member]
Warrants outstanding, measurement input	348

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Warrant liability	$ 1,411	$ 1,468
Derivative liabilities	834,457
Convertible notes at fair value	5,814,047	1,156,341
Fair Value, Inputs, Level 1 [Member]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 2 [Member]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Warrant liability	1,411	1,468
Derivative liabilities	834,457
Convertible notes at fair value	$ 5,814,047	$ 1,156,341

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Convertible Notes Payable [Member]
Beginning balance		$ 1,156,341	$ 1,925,959
Purchases and issuances		688,274	472,029
Day one loss on value of hybrid instrument	[1]	926,109	2,021,041
Loss from change in fair value	[1]	3,423,935	130,344
Gain on settlement			(958,581)
Debt discount		(22,344)
Settlement through issuance of common stock		(83,268)
Conversion to common stock		(275,000)	(2,434,451)
Ending balance		5,814,047	1,156,341
Warrant [Member]
Beginning balance		1,468	5,903
Total gain included in earnings	[2]	(57)	(4,435)
Ending balance		$ 1,411	$ 1,468
[1]	The losses related to the valuation of the convertible notes are included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.
[2]	The gain related to the revaluation of our warrant liability is included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Assumptions and the Significant Terms (Details) - Convertible Notes Payable [Member]	12 Months Ended
	Dec. 31, 2019USD ($)d$ / shares	Dec. 31, 2018USD ($)d$ / shares
Face Amount | $	$ 1,244,204	$ 1,340,026
Minimum [Member]
Conversion Price | $ / shares	$ 0.00010	$ .0002
Percentage of stock price for look-back period	50.00%	40.00%
Look-back period | d	3	3
Maximum [Member]
Conversion Price | $ / shares	$ 0.000293	$ .20
Percentage of stock price for look-back period	60.00%	60.00%
Look-back period | d	25	25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	8	8
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	10	12
Measurement Input, Default Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	20	18
Measurement Input, Default Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	24	20
Measurement Input, Discount Rate [Member] | Minimum [Member]
Long-term debt, measurement input		25.95
Measurement Input, Discount Rate [Member] | Maximum [Member]
Long-term debt, measurement input		27.95

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials	$ 52,183	$ 33,431
Finished Goods	8,177	1,871
Total Inventories	60,360	35,302
Less: Long-term inventory	(52,183)
Current portion	$ 8,177	$ 35,302

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 3,737	$ 5,963

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 216,033	$ 216,033
Less: Accumulated depreciation	(209,270)	(205,533)
Property and equipment, net	6,763	10,500
Computer Equipment [Member]
Property and equipment, gross	25,120	25,120
Furniture and Fixtures [Member]
Property and equipment, gross	34,757	34,757
Lab Equipment [Member]
Property and equipment, gross	53,711	53,711
Telephone Equipment [Member]
Property and equipment, gross	12,421	12,421
Office Equipment - Other [Member]
Property and equipment, gross	16,856	16,856
Leasehold Improvements [Member]
Property and equipment, gross	$ 73,168	$ 73,168

Due to_from Officer (Details Na

Due to/from Officer (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Due to officer	$ 122,812	$ 186,497
Repayment of officers loans	134,015	162,775
Loans from officer	5,000	105,900
Accrued interest expense for amount due to officer	6,330	7,674
Bad debt expense	61,789	505,470
Company other receivable	564,470	505,470
Rik Deitsch [Member]
Due to officer	$ 122,812	$ 186,497
Bears interest percentage	4.00%	4.00%
Repayment of officers loans	$ 134,015	$ 162,775
Loans from officer	5,000	105,900
Accrued interest expense for amount due to officer	6,330	7,674
Bad debt expense	$ 59,000	$ 505,470

Debts - Schedule of Debt (Detai

Debts - Schedule of Debt (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Note payable- Related Party (Net of discount of $0 and $2,400 respectively) (1)	$ 14,400	$ 12,000
Notes payable - Unrelated third parties (Net of discount of $8,921 and $17,870, respectively) (2)	1,385,163	1,469,690
Convertible notes payable - Unrelated third parties (Net of discount of $17,370 and $29,371, respectively) (3)	872,256	751,955
Convertible notes payable, at fair value (Net of discount of $22,344 and $0, respectively) (4)	5,814,047	1,156,341
Other advances from an unrelated third party (5)	175,000
Ending balances	8,260,866	3,389,986
Less: Long-term portion-Notes payable-Unrelated third parties		(51,410)
Less: Long-term portion-Convertible Notes payable-Unrelated third parties	(907,912)
Current portion	$ 7,352,954	$ 3,338,576

Debts - Schedule of Debt (Det_2

Debts - Schedule of Debt (Details) (Parenthetical)	Jun. 22, 2021USD ($)	Jun. 01, 2021USD ($)shares	Apr. 26, 2021USD ($)shares	Mar. 31, 2021USD ($)$ / shares	Feb. 25, 2021USD ($)shares	Oct. 05, 2020USD ($)shares	Sep. 21, 2020USD ($)shares	Jul. 31, 2020USD ($)$ / shares	Mar. 03, 2020USD ($)shares	Feb. 18, 2020USD ($)shares	Jan. 21, 2020USD ($)shares	Jun. 06, 2019USD ($)shares	May 31, 2019USD ($)shares	May 06, 2019USD ($)shares	Feb. 15, 2019USD ($)	Aug. 14, 2018USD ($)shares	Jul. 31, 2018USD ($)shares	Jun. 30, 2018USD ($)	May 31, 2018USD ($)shares	Feb. 28, 2018USD ($)	Jul. 31, 2017USD ($)	Jul. 18, 2017USD ($)	Jun. 27, 2017USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2017USD ($)	Mar. 28, 2016USD ($)	Mar. 19, 2014USD ($)	Jun. 30, 2012USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Apr. 30, 2021USD ($)	Mar. 31, 2021USD ($)$ / shares	Feb. 28, 2021USD ($)	Oct. 31, 2020USD ($)$ / shares	Aug. 31, 2020USD ($)	Jan. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Aug. 31, 2019USD ($)	Jun. 30, 2019USD ($)shares	Feb. 28, 2019USD ($)shares	Jan. 31, 2019USD ($)	Sep. 30, 2018USD ($)shares	Aug. 31, 2018USD ($)dshares	Jul. 31, 2018USD ($)dshares	Jun. 30, 2018USD ($)dshares	May 31, 2018USD ($)dshares	Apr. 30, 2018USD ($)dshares	Mar. 31, 2018USD ($)d	Feb. 28, 2018USD ($)dshares	Nov. 30, 2017USD ($)shares	Oct. 31, 2017USD ($)shares	Sep. 30, 2017USD ($)	Aug. 31, 2017USD ($)shares	Jul. 31, 2017USD ($)shares	May 31, 2017USD ($)dshares	Apr. 30, 2017USD ($)shares	Dec. 31, 2016USD ($)dshares	Jun. 30, 2016USD ($)	Apr. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Feb. 29, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Jul. 31, 2017USD ($)shares	Apr. 30, 2021USD ($)shares	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Mar. 31, 2012USD ($)shares	May 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2019USD ($)d$ / sharesshares	Dec. 31, 2018USD ($)d$ / sharesshares	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2020USD ($)shares	Nov. 30, 2020USD ($)$ / shares	Sep. 30, 2020USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	Feb. 28, 2020USD ($)$ / shares	Nov. 30, 2019USD ($)$ / shares	Jul. 31, 2019USD ($)	Jun. 17, 2019USD ($)shares	Oct. 31, 2018USD ($)	Jul. 12, 2018USD ($)	Apr. 28, 2018USD ($)shares	Mar. 18, 2018$ / shares	Oct. 20, 2017USD ($)	Oct. 12, 2017USD ($)	Jul. 26, 2017USD ($)$ / shares	Jun. 30, 2017USD ($)	Feb. 28, 2017$ / shares	Jan. 31, 2017USD ($)	Oct. 31, 2016USD ($)	Sep. 26, 2016USD ($)	Aug. 31, 2016USD ($)shares	Jul. 31, 2016USD ($)$ / shares	May 31, 2016USD ($)	Apr. 30, 2014$ / sharesshares	Sep. 12, 2013$ / sharesshares	Sep. 03, 2013$ / sharesshares	Aug. 31, 2013USD ($)	Mar. 31, 2013$ / sharesshares	Dec. 31, 2012USD ($)	Feb. 15, 2012USD ($)	Dec. 31, 2011USD ($)	Aug. 15, 2011USD ($)	Aug. 02, 2011USD ($)	Dec. 31, 2010USD ($)	Feb. 28, 2010	Jan. 31, 2010
Notes payable																																				$ 8,260,866																														$ 3,389,986				$ 8,260,866		$ 8,260,866	$ 3,389,986
Accrued interest																																																																								29,948
Interest expense, debt																																																																								244,278	574,334
Gain loss on extinguishment of debt																																																																								92,621	905,758
Debt instrument accrued interest																																																																								$ 66,460
Common stock, shares, issued | shares																																				5,876,746,111																					1,000,000									4,046,746,110				5,876,746,111		5,876,746,111	4,046,746,110		1,000,000
Common stock issued value																																				$ 5,876,746																														$ 4,046,746				$ 5,876,746		$ 5,876,746	$ 4,046,746
Amortization of debt discount																																																																								100,810	378,754
Repayments of convertible debt																																																																								$ 13,500	3,000
Stock issued price per shares | $ / shares																																				$ 0.18																																		$ 0.18		$ 0.18
Debt conversion, converted instrument, shares issued | shares												250,000,000	250,000,000	250,000,000
Number of shares issued for conversion of debt												$ 100,000	$ 100,000	$ 75,000
Debt instrument conversion feature																																																																									249,113
Number of warrants issued | shares																																																																																																			100,000	375,000	500,000		65,000
Warrant exercise price | $ / shares																																																																																																			$ 0.025	$ 0.01	$ 0.025		$ 0.01
Fair Value of Warrants																																				$ 7,370				$ 8,147																																7,370	0
Month of expiration																																																																																																			Apr. 9, 2019	Sep. 12, 2018	Sep. 3, 2018		Mar. 22, 2018
Other advances from an unrelated third party																																																																						$ 175,000		175,000
Warrant [Member]
Debt principal amount																																				$ 22,000				70,000																														$ 22,000		$ 22,000
Debt instrument conversion feature																																																																									$ 249,113
Warrant exercise price | $ / shares																																				$ 0.001																																		$ 0.001		$ 0.001
Minimum [Member]
Warrant exercise price | $ / shares																																				0.001																														$ 0.005				0.001		0.001	$ 0.005
Maximum [Member]
Warrant exercise price | $ / shares																																				$ 0.03																														$ 0.05				$ 0.03		$ 0.03	$ 0.05
Subsequent Event [Member]
Other advances from an unrelated third party																																																																					$ 50,000
Subsequent Event [Member] | Warrant [Member]
Debt discount																																																																													$ 7,500
Warrant exercise price | $ / shares																																																																													$ 0.002
Warrant outstanding																																																																													$ 30,417
Fair Value of Warrants																																	$ 8,633	$ 20,848
NonRelatedPartyFiveMember
Notes payable																																																																																					$ 220,506
Debt instrument, interest rate, stated percentage																																																																																					0.25%
Non Related Party Ten [Member]
Notes payable																																																																		$ 120,000							$ 120,000
Note Holder [Member] | Subsequent Event [Member]
Debt conversion, converted instrument, shares issued | shares		5,700,000	27,070,000		137,700,000	107,817,770	107,133,333		67,380,000	250,000,000	250,000,000
Number of shares issued for conversion of debt		$ 35,340	$ 192,197		$ 1,500,930	$ 64,691	$ 171,413		$ 599,682	$ 275,000	$ 150,000
Settlement Agreement [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Cash settlement																																																																														$ 84,000
Promissory Note [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Common stock, shares, issued | shares																																																																															10,000,000
Common stock issued value																																																																															$ 119,700
Promissory Note [Member] | Unrelated Third Parties [Member]
Debt discount																																																																										$ 10,000
Gain loss on extinguishment of debt																																											$ 41,500
Debt principal amount																																																																										60,000
Debt default, amount																																											$ 60,000
Common stock, shares, issued | shares																																											145,000,000
Common stock issued value																																											$ 101,500
Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																																									12.00%																		12.00%
Accrued interest																																																	$ 2,820														$ 63,001
Common stock, shares, issued | shares																	105,157,409																											105,157,409
Common stock issued value																	$ 147,220																											$ 147,220
Convertible notes payable																																																									$ 110,000									32,400							32,400		$ 110,000
Debt maturity date																																																									Sep. 8, 2017
Debt conversion, converted instrument, shares issued | shares																																																															179,800,000
Debt conversion principle amount																																																	46,999
Debt instrument conversion feature																																																															$ 298,575
Conversion percentage																																																									60.00%
Trading days | d																																																									25
Convertible Debtentures [Member] | Non Related Party Twelve [Member]
Convertible notes payable																											$ 500,000													1,000,000																										27,000							27,000
Repayments of convertible debt																											15,000																																														3,000
Debt instrument convertible debt percentage																																																																																							8.00%
Stock issued price per shares | $ / shares																																																																																							$ 0.20
Deposit liabilities, accrued interest																																																																		11,412							11,412
Convertible Debtentures [Member] | Non Related Party Thirteen [Member]
Convertible notes payable																											1,000,000
Repayments of convertible debt																											$ 30,000
Convertible Debtentures [Member] | Non Related Party Fourteen [Member]
Debt discount																																				$ 0							3,800																							950				$ 0		$ 0	950
Notes payable																				$ 65,600																													65,600
Accrued interest																																											10,476
Debt instrument, unamortized discount net issuance costs																$ 1,035
Amortization of debt discount																																																																	$ 950								2,850
Convertible notes payable																				$ 65,600																76,076							$ 76,076						$ 65,600																	75,126				76,076		76,076	75,126																	$ 56,567			$ 56,567				$ 50,000
Debt instrument convertible debt percentage																				2.50%																							2.50%						2.50%																																												2.50%				2.00%
Stock issued price per shares | $ / shares																																																																																										$ 0.05							$ 0.05
Debt conversion, converted instrument, shares issued | shares																1,000,000																											5,000,000
Convertible Debtentures [Member] | Settlement Agreement [Member] | Non Related Party Twelve [Member]
Cash settlement																																								38,412
Back and End Note [Member]
Debt instrument, interest rate, stated percentage																																															8.00%
Debt principal amount																																				71,500											$ 100,000																			65,000				71,500		71,500	65,000
Convertible notes payable																																				458,957											$ 65,000																			115,165				458,957		458,957	115,165
Debt instrument convertible debt percentage																																															24.00%
Conversion percentage																																															60.00%
Trading days | d																																															25
Derivative loss																																															$ 110,700
Back and End Note [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																		8.00%																											8.00%
Debt principal amount																																				66,000																														60,000				66,000		66,000	60,000
Convertible notes payable																		$ 60,000																		417,577									$ 60,000																					105,334				417,577		417,577	105,334
Debt instrument convertible debt percentage																		24.00%																											24.00%
Conversion percentage																																													60.00%
Trading days | d																																													25
Derivative loss																		$ 68,067																											$ 68,067
Restatement of Promissory Notes [Member] | Subsequent Event [Member]
Debt instrument, interest rate, stated percentage								2.00%
Debt principal amount								$ 166,926
Debt instrument accrued interest																																$ 23,258
Restatement of Promissory Notes [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member]
Debt discount																																			$ 10,000
Debt instrument, interest rate, stated percentage																																			2.50%
Debt principal amount																																			$ 60,000
Debt instrument accrued interest																																			88,225
Note Payable - Related Party [Member]
Debt discount																																				0																														2,400				0		0	2,400
Note Payable Unrelated Party [Member]
Debt discount																																				8,921																														17,870				8,921		8,921	17,870
Non Related Parties Convertible Notes Payable [Member]
Debt discount																																				37,370																														29,371				37,370		37,370	29,371
Convertible Notes Payable [Member]
Debt discount																																				22,344				5,000																										0				22,344		22,344	0
Notes payable																																																																		751,955							751,955
Debt instrument, unamortized discount net issuance costs																																				5,000																														29,371				5,000		5,000	$ 29,371
Amortization of debt discount																																						$ 8,200																												589,829					$ 28,421
Convertible notes payable																																	511,319			$ 70,000				$ 70,000																														$ 70,000		$ 70,000
Debt instrument convertible debt percentage																																								0.05%
Number of warrants issued | shares																																				110,000,000																																		110,000,000		110,000,000
Warrant exercise price | $ / shares																																				$ 0.001																																		$ 0.001		$ 0.001
Warrant outstanding																																				$ 8,147																																		$ 8,147		$ 8,147
Amortization																																																																		$ 88,887					232,000
Convertible Notes Payable [Member] | Warrant [Member]
Number of warrants issued | shares																																				44,000,000				110,000,000																														44,000,000		44,000,000
Warrant exercise price | $ / shares																																				$ 0.001																																		$ 0.001		$ 0.001
Fair Value of Warrants																																				$ 7,370				$ 8,147
Month of expiration																																				Aug. 31, 2020				Aug. 31, 2019																														Aug. 31, 2020		Aug. 31, 2020
Convertible Notes Payable [Member] | Common Stock [Member]
Debt instrument, unamortized discount net issuance costs																																				$ 6,400																																		$ 6,400		$ 6,400
Common stock, shares, issued | shares																																				6,000,001																																		6,000,001		6,000,001
Common stock issued value																																				$ 1,800																																		$ 1,800		$ 1,800
Convertible Notes Payable [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares																																				$ 0.00010																														$ .0002				$ 0.00010		$ 0.00010	$ .0002
Conversion percentage																																																																								50.00%	40.00%
Trading days | d																																																																								3	3
Convertible Notes Payable [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares																																				$ 0.000293																														$ .20				$ 0.000293		$ 0.000293	$ .20
Conversion percentage																																																																								60.00%	60.00%
Trading days | d																																																																								25	25
Convertible Notes Payable [Member] | Subsequent Event [Member] | Warrant [Member]
Debt discount																																	$ 29,481
Warrant exercise price | $ / shares																																	$ 0.001
Convertible Notes Payable [Member] | Subsequent Event [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares				$ 0.0003																									$ 0.0008		$ 0.0003
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																																							8.00%
Accrued interest																				$ 63,144																$ 3,232
Debt principal amount																																				12,629																														$ 29,381				$ 12,629		$ 12,629	$ 29,381
Non-payment penalty charges																				$ 12,442																													$ 12,442	$ 6,400
Convertible notes payable																		34,060																		62,253									34,060					856					$ 64,000											63,315				62,253		62,253	63,315
Debt maturity date																																																							May 4, 2018
Interest payable																																				$ 9,782																														7,138				9,782		9,782	7,138
Debt instrument convertible debt percentage																																																							20.00%
Deposit liabilities, accrued interest																		8,607																											$ 8,607					21,399
Debt conversion, converted instrument, shares issued | shares																																				800,000,000									50,670,000
Debt conversion principle amount																																				$ 16,752
Debt instrument conversion feature																																													$ 70,938
Conversion percentage																																																							60.00%
Trading days | d																																																							20
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt discount																																				17,370																																		17,370		17,370
Debt instrument, unamortized discount net issuance costs																																				2,000																																		2,000		2,000									$ 12,500
Debt principal amount																																				736,180																																		736,180		736,180
Convertible notes payable																																				$ 22,000																																		$ 22,000		$ 22,000									$ 137,500
Stock issued price per shares | $ / shares																																				$ 0.0002																																		$ 0.0002		$ 0.0002									$ 0.000275
Amortization																																																																								$ 55,222
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member]
Debt discount								1,900																									$ 1,650	7,550	6,250																																												6,250	$ 2,000
Debt principal amount								20,900																									16,500	$ 38,500	68,750																																												$ 68,750	$ 22,000
Repayments of convertible debt																														$ 19,500	$ 19,500
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member]
Accrued interest																																																																								12,150	8,177
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member] | Subsequent Event [Member]
Convertible notes payable								$ 60,000																											$ 60,000
Convertible Notes Payable [Member] | Non Related Party Fifteen [Member]
Debt instrument, unamortized discount net issuance costs																																																			$ 10,000
Debt default, amount																																																			$ 3,300
Common stock, shares, issued | shares																																																			5,000,000
Convertible notes payable																																																			$ 60,000
Convertible Notes Payable [Member] | Non Related Party Twenty [Member]
Debt discount																																																																		255,655							255,655
Debt instrument, unamortized discount net issuance costs																																																																		$ 62,950							$ 62,950
Common stock, shares, issued | shares																																																																		10,250,000							10,250,000
Common stock issued value																																																																		$ 6,542							$ 6,542
Amortization of debt discount																																																																									62,950
Convertible notes payable																																																																		$ 618,250							618,250
Debt instrument conversion feature																																																																									$ 249,113
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Minimum [Member]
Debt instrument convertible debt percentage																																																																		0.03%							0.03%
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Maximum [Member]
Debt instrument convertible debt percentage																																																																		0.10%							0.10%
Convertible Notes Payable [Member] | 16 Unrelated Third Parties [Member]
Convertible notes payable																																				$ 574,550																																		$ 574,550		574,550
Convertible Notes Payable [Member] | Note Holder [Member] | Subsequent Event [Member]
Debt discount																																	$ 9,200
Debt instrument convertible price per share | $ / shares								$ 0.00052																									$ 0.0005		$ 0.0005																																												$ 0.0005	$ 0.0003
Debt principal amount																													$ 100,810																																																20,000
Stock issued during period, restricted stock | shares																													237,850,000																																500,000,000
Stock issued during period, restricted stock value																													$ 118,925																																$ 175,000
Debt instrument fair value																													$ 2,328,149																																$ 425,000																$ 120,000
Convertible Notes Payable [Member] | Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member]
Repayments of notes payable																																																																										60,000	$ 40,000
Debt principal amount																																				20,000																														$ 20,000				20,000		20,000	$ 20,000
Convertible notes payable																										$ 120,000										$ 56,373																														$ 47,481				$ 56,373		56,373	$ 47,481
Extinguishment debt extinguishment assets payments																										7,000
Derivative, collateral, obligation to return cash																										$ 36,000
Convertible Notes Payable [Member] | Note Agreement [Member]
Debt principal amount																																								$ 1,000,000
Proceeds from loan																																																																								$ 372,374
Convertible Notes Payable [Member] | Note Agreement [Member] | Subsequent Event [Member]
Stock issued during period, restricted stock | shares																																																																232,150,000
Stock issued during period, restricted stock value																																																																$ 116,075
Debt instrument fair value																														2,292,809																																		2,292,809
Proceeds from loan	$ 122,362
Convertible Notes Payable [Member] | Promissory Note [Member]
Debt principal amount																																									$ 75,000
Convertible notes payable																																									60,000
Interest payable																																									15,900
Derivative loss																																									75,900
Convertible Notes Payable [Member] | Promissory Note [Member] | Settlement Agreement [Member] | Non Related Party Fifteen [Member]
Common stock, shares, issued | shares																																				1,000,000																														1,000,000				1,000,000		1,000,000	1,000,000
Common stock issued value																																				$ 1,500																														$ 1,500				$ 1,500		$ 1,500	$ 1,500
Convertible notes payable																																				60,000																														60,000				60,000		60,000	60,000
Convertible Notes Payable [Member] | Convertible Promissory Note [Member] | Non Related Party Twenty Five [Member]
Debt discount																																				33,516																																		33,516		33,516
Convertible notes payable																																				540,000																																		540,000		540,000
Convertible Notes Payable [Member] | Convertible Debtentures [Member]
Debt instrument, interest rate, stated percentage																																																									8.00%																		8.00%
Debt principal amount																																				38,301																														34,819				38,301		38,301	34,819
Convertible notes payable																																				246,819																					$ 49,819									62,508				246,819		246,819	62,508		$ 49,819
Debt maturity date																																																									Feb. 13, 2019
Debt instrument convertible debt percentage																																																									24.00%																		24.00%
Conversion percentage																																																									60.00%
Trading days | d																																																									25
Convertible Notes Payable [Member] | Convertible Debenture [Member] | Restricted Stock [Member]
Debt principal amount																																										$ 15,000																									$ 15,000				15,000
Debt conversion, converted instrument, shares issued | shares																																										52,244,433
Number of shares issued for conversion of debt																																										$ 37,011
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member]
Repayments of convertible debt																																									$ 75,900
Conversion percentage																																									50.00%
Note Payable One [Member]
Interest expense, debt																																																																								17,747	15,772
Note Payable One [Member] | Promissory Note [Member]
Notes payable																																				14,400																														12,000				14,400		14,400	12,000	12,000
Debt instrument, unamortized discount net issuance costs																																				0																														2,400				0		0	2,400	2,000
Note Payable One [Member] | Director [Member]
Notes payable																																																																																																													$ 200,000
Debt instrument, interest rate, stated percentage																																																																																																														12.00%	10.00%
Accrued interest																																																																								159,555	141,808
Note Payable Two [Member]
Notes payable																																				1,385,163																														1,469,690				1,385,163		1,385,163	1,469,690
Debt instrument, unamortized discount net issuance costs																																				8,921																														17,870				8,921		8,921	17,870
Common stock issued value																																																							$ 42,500
Note Payable Two [Member] | UniversityCentreWestLtdMember
Debt instrument rent expenses																																																																																																								$ 55,410
Note Payable Two [Member] | Related Party [Member]
Notes payable																																																										$ 50,000																																								$ 75,000
Debt instrument, interest rate, stated percentage																																																										2.00%																																								2.00%
Accrued interest																																																																								49,967	37,801
Repayments of notes payable																																																								$ 25,000
Debt principal amount																																				50,000																														50,000				50,000		50,000	50,000
Common stock, shares, issued | shares																																																								5,000,000
Note Payable Two [Member] | Related Party One [Member]
Accrued interest																																																																								43,166	31,000
Debt principal amount																																				50,000																														50,000				50,000		50,000	50,000
Note Payable Two [Member] | Unrelated Third Party [Member]
Notes payable																																																																																								$ 180,250
Debt instrument, interest rate, stated percentage																																																																																								2.50%
Note Payable Two [Member] | NonRelatedPartyFiveMember
Notes payable																					$ 200,000																																	$ 200,000									200,000																												$ 12,500
Debt instrument, interest rate, stated percentage																																																					15.00%																																						10.00%
Accrued interest																																																																								3,212	1,944
Debt issuance costs, gross																					5,500																																	5,500									5,500
Note Payable Two [Member] | Non Related Party Two [Member]
Debt discount																																																																																			$ 3,945
Accrued interest																																																																									282,983
Debt instrument, unamortized discount net issuance costs																																				3,616																														329				3,616		3,616	329
Common stock, shares, issued | shares																																																																																			10,000,000
Amortization of debt discount																																																																								1,474	4,421
Note Payable Two [Member] | Non Related Party Two [Member] | Subsequent Event [Member]
Debt discount																																																																												$ 5,895
Notes payable																																																																												$ 333,543
Common stock, shares, issued | shares																																																																												333,543
Note Payable Two [Member] | Non Related Party Eight [Member]
Notes payable																																																				$ 51,000
Accrued interest																																																				8,500
Interest expense, debt																																																				201,250
Repayments of notes payable																																																		8,500
Common stock, shares, issued | shares																																																							187,500,000
Common stock issued value																																																							$ 243,750
Note Payable Two [Member] | Non Related Party Nine [Member]
Debt discount																																				8,254																														4,127				8,254		8,254	4,127
Notes payable																																				60,000																														61,746				60,000		60,000	61,746
Debt instrument, unamortized discount net issuance costs																																				0											10,000																			$ 8,254				0		0	8,254									$ 10,000
Note Payable Two [Member] | Non Related Party Nine [Member] | Minimum [Member]
Amortization of debt discount																																																																								1,587	10,378
Note Payable Two [Member] | Non Related Party Nine [Member] | Maximum [Member]
Amortization of debt discount																																																																								6,667	$ 15,500
Long-term debt, maturities																																											$ 76,076
Note Payable Two [Member] | Non Related Party Ten [Member]
Notes payable																																				120,000																																		120,000		120,000
Common stock, shares, issued | shares																																																																		1,500,000							1,500,000
Common stock issued value																																																																		$ 2,250							$ 2,250
Note Payable Two [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Debt discount																																																																															$ 20,000
Notes payable																																																																															50,000
Debt instrument, unamortized discount net issuance costs																																																																															$ 120,000
Common stock, shares, issued | shares																																																																															125,000,000
Note Payable Two [Member] | Non Related Party Eleven [Member]
Notes payable																																																		18,000
Debt instrument, unamortized discount net issuance costs																																																		$ 3,000
Note Payable Two [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges																																																																				$ 100,000
Note Payable Two [Member] | Southridge Partners, LLP [Member]
Notes payable																																																																																																						$ 281,772
Noncash transaction, value consideration received																												$ 281,772
Note Payable Two [Member] | Settlement Agreement [Member] | NonRelatedPartyFiveMember
Notes payable																																																																										191,329
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Two [Member]
Notes payable																																				333,543																														282,983				333,543		333,543	282,983
Accrued interest																																																																								25,127	2,830
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Four [Member]
Accrued interest																																																																								39,466	27,300
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member]
Notes payable																																				92,728																														$ 135,426				92,728		92,728	135,426
Repayments of notes payable																		130,401																																																						42,698	$ 34,976
Repayments of lines of credit																		40,000
Cash settlement																		$ 20,927																											$ 20,927
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member] | Subsequent Event [Member]
Repayments of notes payable								$ 5,000
Repayments of lines of credit								$ 2,000
Outstanding notes payable																														33,874																																		33,874
Cash settlement																														$ 130,401																																		$ 130,401
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Nine [Member]
Common stock, shares, issued | shares																																																																		10,000,000							10,000,000
Common stock issued value																																																																		$ 3,000							$ 3,000
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Eleven [Member]
Accrued interest																																																																								2,000	0
Repayments of notes payable																																																																								5,600	18,000
Common stock, shares, issued | shares																																																		7,000,000
Note Payable Two [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Notes payable																																																																																																									$ 50,000		$ 50,000	$ 350,000
Repayments of lines of credit																																																																				$ 25,000
Debt principal amount																																																																																																										$ 175,000
Non-payment penalty charges																																																																																																										$ 25,000
Sale of stock, number of shares | shares																																																																				142,858
Note Payable Two [Member] | Promissory Note [Member]
Notes payable																																																											$ 10,000
Debt instrument, interest rate, stated percentage																																																											10.00%
Debt instrument accrued interest																																																																								3,755	2,739
Note Payable Two [Member] | Promissory Note [Member] | Unrelated Third Party [Member]
Notes payable																																																																																																$ 150,000
Debt instrument, interest rate, stated percentage																																																																																																2.50%
Note Payable Two [Member] | Promissory Note [Member] | NonRelatedPartyOneMember
Debt discount																																																																																																$ 2,765
Notes payable																																																																																			$ 282,983
Debt instrument, interest rate, stated percentage																																																																																			2.00%
Repayments of notes payable																	$ 220,506
Common stock, shares, issued | shares																	5,000,000																											5,000,000																																																				2,000,000
Common stock issued value																	$ 5,500																											$ 5,500
Amortization of debt discount																																																																									2,765
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Three [Member]
Notes payable																																				15,000					$ 60,000																									75,000				15,000		15,000	75,000																						$ 75,000
Debt instrument, interest rate, stated percentage																																																																																															10.00%
Accrued interest																																																																								1,371	17,271
Debt instrument accrued interest																																									15,900
Long-term debt, maturities																																									$ 15,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Four [Member]
Notes payable																																																																																														$ 50,000
Debt instrument, interest rate, stated percentage																																																																																														2.00%
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Seven [Member]
Notes payable																					50,000															50,000																		$ 50,000									$ 50,000			50,000				50,000		50,000	50,000
Amortization of debt discount																					$ 10,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member]
Notes payable																																				30,000																36,000																		30,000		30,000						33,000
Accrued interest																																																																								4,500	6,000
Debt instrument, unamortized discount net issuance costs																																					$ 6,000					6,000										6,000															$ 6,000				$ 6,000							$ 3,000
Repayments of notes payable																																					$ 5,000					$ 7,000										$ 1,500
Amortization of debt discount																																																																								7,500	4,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member] | Subsequent Event [Member]
Notes payable				$ 30,000																											$ 30,000
Debt instrument, interest rate, stated percentage				12.00%																											12.00%
Debt instrument convertible price per share | $ / shares				$ 0.01																											$ 0.01
Repayments of notes payable				$ 1,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Nine [Member]
Debt discount																																																			3,200
Notes payable																																																			50,000																							$ 60,000
Debt instrument, unamortized discount net issuance costs																																																			$ 10,000
Common stock, shares, issued | shares																																																			5,000,000																																			1,000,000
Common stock issued value																																																																																						$ 1,700
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member]
Debt discount																																																		$ 5,600
Notes payable																																																		120,000
Debt instrument, unamortized discount net issuance costs																																																		$ 20,000
Common stock, shares, issued | shares																																																		10,000,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Debt discount																																																																															$ 14,000
Notes payable																																																																															$ 70,000
Common stock, shares, issued | shares																																																																															36,000,000
Common stock issued value																																																																															$ 119,700
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eleven [Member]
Notes payable																																																		$ 2,900
Common stock, shares, issued | shares																																																		5,000,000
Note Payable Two [Member] | Promissory Note Two [Member]
Notes payable															$ 101,818																					90,500																																		90,500		90,500																	$ 201,818
Debt instrument, interest rate, stated percentage																																																																																									12.00%
Accrued interest															21,023																																																									21,023
Debt instrument convertible price per share | $ / shares																																																																																												$ 0.008
Repayments of notes payable																								$ 6,365
Repayments of lines of credit															$ 104,000																																																									13,500
Gain loss on extinguishment of debt																																																																								18,841
Outstanding notes payable																																				91,156																																		91,156		91,156
Note Payable Two [Member] | Promissory Note Two [Member] | Settlement [Member]
Accrued interest																																																																								29,948
Note Payable Two [Member] | Reverse Stock Split [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges																																																																				$ 350,000
Sale of stock, number of shares | shares																																																																				5,714,326
Cash settlement																																																																				$ 450,000
Debt default, amount																																																																				$ 100,000
Note Payable Two [Member] | Note Holder [Member] | Non Related Party Nine [Member]
Debt discount																																															8,678
Debt instrument, unamortized discount net issuance costs													10,000																																		18,678																																					$ 10,000
Debt default, amount													$ 2,381
Common stock, shares, issued | shares													5,000,000
Common stock issued value																																															$ 60,000
Note Payable Two [Member] | Director [Member] | Promissory Note Two [Member]
Notes payable																																				160,633																														192,974				160,633		160,633	192,974																		$ 8,844					$ 200,000
Debt instrument, interest rate, stated percentage																																																																																																12.00%
Accrued interest																																																																								50,971	40,033
Note Payable Two [Member] | Former Director [Member] | Promissory Note Two [Member]
Notes payable																																																																																																$ 100,000
Convertible Loans [Member]
Debt discount																																				17,370																														29,371				17,370		17,370	29,371
Notes payable																																				872,256																														751,955				872,256		872,256	751,955
Convertible Notes Payable Three of the Notes [Member] | Unrelated Third Parties [Member]
Repayments of convertible debt																																				13,500
Convertible Notes Payable Six of the Notes [Member] | Unrelated Third Parties [Member]
Repayments of convertible debt																																				$ 87,100
Debt conversion, converted instrument, shares issued | shares																																				800,000,000
Convertible Loans One [Member]
Debt instrument, unamortized discount net issuance costs																																				$ 22,344																														0				22,344		22,344	0
Convertible notes payable																																				5,814,047																														1,156,341				5,814,047		5,814,047	1,156,341
Convertible Loans One [Member] | Unrelated Third Parties [Member]
Debt instrument, interest rate, stated percentage																																																												4.00%
Convertible notes payable																							$ 80,000																																					$ 80,000
Debt maturity date																																																												Dec. 7, 2016
Interest payable																							$ 4,971
Debt conversion, converted instrument, shares issued | shares																																																	109,876,500				164,935,000	164,935,000
Debt conversion principle amount																																																	$ 29,646				$ 55,325	$ 55,325
Number of shares issued for conversion of debt																																																	$ 462,625				$ 225,143	$ 225,143
Convertible Redeemable Note [Member]
Debt instrument, interest rate, stated percentage																				8.00%																													8.00%
Convertible notes payable																				$ 49,146																													$ 49,146
Debt maturity date																																																	Feb. 13, 2019
Interest payable																				$ 3,276																													$ 3,276
Debt conversion, converted instrument, shares issued | shares																																														65,885,713	65,885,713
Debt conversion principle amount																																														$ 49,146	$ 49,146
Number of shares issued for conversion of debt																																														$ 145,161	$ 145,161
Convertible Redeemable Note [Member] | Unrelated Third Parties [Member]
Notes payable																																																										$ 50,000
Debt instrument, interest rate, stated percentage																				8.00%			8.00%																										8.00%									8.00%
Debt principal amount																				$ 150,000																													$ 150,000
Convertible notes payable																							$ 84,971
Debt maturity date																							Jun. 27, 2018																										Feb. 13, 2019									Jun. 16, 2017
Interest payable																				$ 6,000																													$ 6,000									$ 4,800
Debt conversion, converted instrument, shares issued | shares																			228,000,000																										120,891,284	120,891,284																					206,988,570
Debt conversion principle amount																			$ 54,800																										$ 70,000	$ 70,000																					$ 86,000
Number of shares issued for conversion of debt																			$ 319,200																										$ 200,475	$ 200,475																					$ 206,988,570
Convertible Debenture [Member]
Debt instrument, interest rate, stated percentage																						8.00%		8.00%	8.00%
Convertible notes payable																						$ 150,000		$ 80,000	$ 80,000
Debt maturity date																						Jul. 18, 2018			Mar. 30, 2018
Debt conversion, converted instrument, shares issued | shares																																																	70,123,500
Debt conversion principle amount																																																	$ 30,854
Number of shares issued for conversion of debt																																																	294,885
Convertible Debenture [Member] | Unrelated Third Parties [Member]
Debt instrument, interest rate, stated percentage																																																										8.00%
Convertible notes payable																																																										$ 72,000
Debt maturity date																																																										Jun. 20, 2017
Convertible Debenture [Member] | Labrys [Member]
Debt instrument, interest rate, stated percentage																																																			12.00%				12.00%
Gain loss on extinguishment of debt																																																	$ 958,581
Convertible notes payable																																																			$ 45,000				$ 90,000
Debt maturity date																																																			Nov. 3, 2017				Jul. 19, 2017
Debt conversion, converted instrument, shares issued | shares																																																	45,000,000	62,059,253
Debt conversion principle amount																																																	$ 78,943	$ 11,057
Number of shares issued for conversion of debt																																																	247,500	$ 51,732
Debt instrument conversion feature																																																	$ 1,206,081
Convertible Promissory Note [Member]
Debt discount																																				22,344																																		22,344		22,344
Debt instrument, unamortized discount net issuance costs																																							$ 40,000																							$ 40,000
Repayments of notes payable																																								27,000
Debt principal amount																																				272,374																																		272,374		272,374
Amortization of debt discount																																							4,688																																	22,344
Convertible notes payable																																				907,912			240,000																							$ 240,000								907,912		907,912
Interest payable																																								11,412
Debt conversion, converted instrument, shares issued | shares																																																														750,000,000
Debt conversion principle amount																																																														$ 100,000
Number of shares issued for conversion of debt																																																														275,000
Derivative loss																																							$ 240,000	$ 610,210																						$ 240,000
Debt instrument conversion terms																																							The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.	The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.
Stock issued during period, restricted stock | shares																																							16,000,000
Convertible Promissory Note [Member] | Maximum [Member]
Debt principal amount																																								$ 1,000,000
Convertible Promissory Note [Member] | Unrelated Third Party [Member]
Convertible notes payable																																				800,000																																		800,000		800,000
Convertible Promissory Note [Member] | Unrelated Third Parties [Member]
Debt instrument, interest rate, stated percentage																																																											12.00%
Convertible notes payable																																																											$ 33,000
Debt maturity date																																																											Jan. 30, 2018
Debt conversion, converted instrument, shares issued | shares																																													150,000,000						50,125,000
Debt conversion principle amount																																													$ 16,960						$ 16,040
Number of shares issued for conversion of debt																																													$ 180,000						$ 35,596
Convertible Promissory Note [Member] | Note Agreement [Member]
Convertible notes payable																																				$ 103,660																																		103,660		103,660
Debt maturity date																																				Mar. 31, 2023
Convertible Notes Payable One [Member] | Convertible Debtentures [Member]
Debt instrument, interest rate, stated percentage																				8.00%																													8.00%
Debt principal amount																																				$ 220,000																														200,000				220,000		220,000	200,000
Convertible notes payable																				$ 200,000																1,412,175													$ 200,000																	358,665				1,412,175		1,412,175	358,665
Debt maturity date																																																	Feb. 28, 2019
Debt instrument convertible debt percentage																				24.00%																													24.00%
Conversion percentage																																																	60.00%
Trading days | d																																																	25
Derivative loss																				$ 1,646,242																													$ 1,646,242
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																																8.00%
Debt principal amount																																				66,000																																		66,000		66,000
Convertible notes payable																																				417,576												$ 60,000																						417,576		417,576
Debt instrument convertible debt percentage																																																24.00%
Conversion percentage																																																60.00%
Trading days | d																																																25
Derivative loss																																																$ 48,418
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt principal amount																																																																		60,000							60,000
Convertible notes payable																																																																		107,329							107,329
Convertible Notes Payable One [Member] | Back and End Note [Member] | Unrelated Third Party [Member]
Convertible notes payable																																																$ 60,000
Convertible Notes Payable Two [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																			8.00%																											8.00%
Debt principal amount																																				60,000																														60,000				60,000		60,000	60,000
Convertible notes payable																			$ 60,000																	369,372										$ 60,000																				106,681				369,372		369,372	106,681
Debt maturity date																																														May 31, 2019
Debt instrument convertible debt percentage																			24.00%																											24.00%
Conversion percentage																																														60.00%
Trading days | d																																														25
Derivative loss																			$ 59,257																											$ 59,257
Convertible Notes Payable Three [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																											8.00%
Debt principal amount																																				31,500																														31,500				31,500		31,500	31,500
Convertible notes payable																																				183,565							$ 31,500																							55,409				183,565		183,565	55,409
Debt maturity date																																											Aug. 31, 2019
Debt instrument convertible debt percentage																																											24.00%
Conversion percentage																																											60.00%
Trading days | d																																											25
Derivative loss																																											$ 23,794
Convertible Notes Payable Four [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																	8.00%																											8.00%
Convertible notes payable																	$ 50,000																			180,176								$ 50,000																						96,157				180,176		180,176	96,157
Debt maturity date																																												Jul. 31, 2019
Debt instrument convertible debt percentage																	24.00%																											24.00%
Conversion percentage																																												55.00%
Trading days | d																																												15
Derivative loss																	$ 46,734																											$ 46,734
Convertible Notes Payable Five [Member] | Convertible Debtentures [Member] | Non Related Party Twenty Two[Member]
Debt instrument, interest rate, stated percentage																																											8.00%
Convertible notes payable																																				70,635							$ 20,000																							$ 38,297				70,635		70,635	$ 38,297
Debt maturity date																																											Aug. 31, 2019
Debt instrument convertible debt percentage																																											24.00%
Conversion percentage																																											55.00%
Trading days | d																																											15
Derivative loss																																											$ 17,829
Convertible Notes Payable [Member]
Convertible notes payable																																				253,000																																		253,000		253,000
Convertible Notes Payable [Member] | Four Tranches [Member]
Convertible notes payable																																				$ 372,374																																		$ 372,374		$ 372,374

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jun. 06, 2019	May 31, 2019	May 06, 2019	Jun. 30, 2018	Oct. 30, 2017	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	May 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Sep. 30, 2018	Aug. 31, 2018	Aug. 30, 2018	Jul. 30, 2018	Jun. 30, 2018	May 31, 2018	Apr. 30, 2018	Feb. 28, 2018	Jan. 31, 2018	Oct. 31, 2017	Jun. 30, 2017	May 31, 2017	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2019	Mar. 07, 2018	Mar. 06, 2018	Jul. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Apr. 30, 2014	Sep. 12, 2013	Sep. 03, 2013	Mar. 31, 2013
Common stock, shares authorized						8,000,000,000																			8,000,000,000		8,000,000,000	8,000,000,000	8,000,000,000		8,000,000,000	2,000,000,000
Preferred stock, shares authorized					20,000,000	20,000,000																			20,000,000		20,000,000	20,000,000	20,000,000
Available for distribution, cash per share					$ 0.133
Number of shares issued for conversion of debt, shares	250,000,000	250,000,000	250,000,000
Number of shares issued for conversion of debt	$ 100,000	$ 100,000	$ 75,000
Debt instrument accrued interest																												$ 66,460
Common stock per share value						$ 0.001																			$ 0.001		$ 0.001	$ 0.001	$ 0.001
Stock issued during the period for services																												$ 30,000	$ 120,000
Warrants, exercise price per share																																				$ 0.025	$ 0.01	$ 0.025	$ 0.01
Debt instrument, convertible, beneficial conversion feature																													$ 249,113
Common Stock [Member]
Stock issued during the period for services, shares																												135,000,000	100,000,000
Stock issued during the period for services																												$ 135,000	$ 100,000
Warrant [Member]
Debt instrument, face amount						$ 22,000																						$ 22,000		$ 70,000
Warrants, exercise price per share						$ 0.001																						$ 0.001
Debt instrument, convertible, beneficial conversion feature																													249,113
Restricted Stock [Member]
Equity compensation charge																												$ 21,500
Share-based payment arrangement, nonvested award, cost not yet recognized, amount						$ 8,500																						8,500
Restricted Stock [Member] | Three note holder [Member]
Equity compensation charge																												50,000	70,000
Restricted Stock [Member] | Consultant [Member]
Stock issued during the period for services, shares								15,000,000		120,000,000
Stock issued during the period for services								$ 6,000		$ 24,000
Restricted Stock [Member] | Settlement of Accrued Liabilities and Debt [Member]
Stock issuance during period, shares											81,000,000		145,000,000				187,500,000
Debt instrument, face amount													$ 60,000				$ 42,500
Stock issuance during period, value											$ 32,400		101,500				243,750
Other expense, debt													$ 41,500				$ 201,250
Debt, default penalty																																			$ 110,000
Accrued share issuance cost																													$ 32,400
Restricted Stock [Member] | Settlement of Accrued Liabilities and Debt [Member]
Stock issuance during period, shares													2,800,000
Stock issuance during period, value													$ 2,800
Other expense, debt													1,400
Debt, outstanding fee													$ 4,200
Restricted Stock [Member] | Debt Modification and Penalty [Member]
Stock issuance during period, shares															105,157,409			1,000,000	105,157,409
Debt instrument, face amount																		$ 50,000
Stock issuance during period, value															$ 147,220			$ 1,700	$ 147,220
Restricted Stock [Member] | Debt Modification and Penalty [Member] | 14 Note Holders [Member]
Stock issuance during period, shares																											33,625,000
Stock issuance during period, value																											$ 25,615
Restricted Stock [Member] | Debt Modification and Penalty [Member] | Three Note Holders [Member]
Stock issuance during period, shares								3,500,000	3,500,000
Stock issuance during period, value								$ 1,050	$ 1,050
Restricted Stock [Member] | Debt Modification and Penalty [Member] | Five Note Holders [Member]
Stock issuance during period, shares																								18,500,000
Stock issuance during period, value																								$ 6,650
Restricted Stock [Member] | Consultant Agreement [Member]
Stock issued during the period for services, shares				100,000,000
Common stock per share value												$ 0.0012														$ 0.0012
Four Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for debt																			4,250,000	4,250,000
Number of shares issued for debt, shares																			$ 9,887	$ 9,887
Notes Payable [Member] | Common Stock [Member]
Number of shares issued for debt							20,000,000	16,000,000	6,000,001
Number of shares issued for debt, shares							$ 5,895	$ 4,688	$ 1,800
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for debt														5,000,000				5,000,000							25,500,000
Number of shares issued for debt, shares														$ 3,800				$ 8,678							$ 9,781
Number of shares issued for conversion of debt, shares																			70,123,500
Number of shares issued for conversion of debt																			$ 294,885
Debt instrument, face amount																			$ 30,854															$ 80,000
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																			109,876,500
Number of shares issued for conversion of debt																			$ 462,625
Debt conversion, original debt, amount																			$ 29,646			$ 84,971
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																	65,885,713	65,885,713	45,000,000
Number of shares issued for conversion of debt																	$ 145,161	$ 145,161	$ 247,500
Debt instrument, face amount																																		$ 49,146
Debt conversion, original debt, amount																			$ 78,943		$ 90,000		$ 90,000
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																120,891,284	120,891,284
Number of shares issued for conversion of debt																$ 200,475	$ 200,475
Debt instrument, face amount				$ 70,000												$ 70,000	$ 70,000																$ 156,000
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																	228,000,000
Number of shares issued for conversion of debt																	$ 319,200
Debt instrument, face amount																	$ 54,800
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																150,000,000
Number of shares issued for conversion of debt																$ 180,000
Debt instrument, face amount				16,960												$ 16,960							33,000
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																50,670,000
Number of shares issued for conversion of debt																$ 70,938
Debt instrument, face amount				$ 34,060												$ 34,060
Debt instrument accrued interest																							$ 6,476
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares																										206,988,570
Number of shares issued for conversion of debt																										$ 176,655
Debt instrument, face amount												$ 86,000														86,000
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares												52,244,433
Number of shares issued for conversion of debt												$ 37,011
Debt instrument, face amount												$ 15,000														$ 15,000
Notes Payable [Member] | Restricted Stock [Member]
Number of shares issued for conversion of debt, shares													300,000,000
Number of shares issued for conversion of debt													$ 300,000
Debt instrument, face amount													$ 72,000
Notes Payable [Member]
Number of shares issued for conversion of debt, shares								750,000,000	750,000,000
Number of shares issued for conversion of debt								$ 275,000	$ 275,000
Debt instrument, face amount		$ 100,000						$ 100,000	$ 100,000
Six Convertible Promissory Notes [Member] | Restricted Stock [Member] | Settlement of Accrued Liabilities and Debt [Member]
Stock issuance during period, shares						800,000,000
Number of shares issued for conversion of debt						$ 29,381
Debt instrument, face amount						87,100																						87,100
Debt conversion, original debt, amount						19,984
Stock issuance during period, value						454,000
Other expense, debt						244,632
Debt, outstanding fee						$ 39,000																						$ 39,000
Series A Preferred Stock [Member]
Stock issuance during period, shares					3,000,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Jun. 06, 2019	May 31, 2019	May 06, 2019
Equity [Abstract]
Number of shares converted	250,000,000	250,000,000	250,000,000
Fair value of debt converted	$ 100,000	$ 100,000	$ 75,000

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Warrants Issued With Debt (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of Warrants	44,000,000	110,000,000	44,000,000
Fair Value of Warrants	$ 7,370	$ 8,147	$ 7,370	$ 0
Month of Expiration	August, 2020	August, 2019
February, 2019 [Member]
Number of Warrants	110,000,000		110,000,000
Fair Value of Warrants			$ 8,147
Month of Expiration			August, 2019
December, 2019 [Member]
Number of Warrants	44,000,000		44,000,000
Fair Value of Warrants			$ 7,370
Month of Expiration			August, 2020

Stock Warrants (Details Narrati

Stock Warrants (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2017	Apr. 04, 2016	Mar. 03, 2016	Apr. 30, 2014	Sep. 12, 2013	Sep. 03, 2013	Mar. 31, 2013
Number of warrants to purchase common stock								100,000	375,000	500,000	65,000
Warrants, exercise price per share								$ 0.025	$ 0.01	$ 0.025	$ 0.01
Warrants, expiration date								Apr. 9, 2019	Sep. 12, 2018	Sep. 3, 2018	Mar. 22, 2018
Notes Payable	$ 8,260,866		$ 8,260,866	$ 3,389,986
Fair value of warrants	7,370	$ 8,147	7,370	0
Three Convertible Notes Payable [Member]
Warrants, exercise price per share		$ 0.001
Notes Payable	$ 22,000	$ 70,000	22,000
Three Year Warrant [Member]
Number of warrants to purchase common stock					600,000	4,000,000
Warrants, exercise price per share					$ 0.005	$ 0.05
Warrants, expiration date					Mar. 30, 2020	Apr. 4, 2019
Notes Payable					$ 80,000
Warrants, term					3 years	3 years
Fair value of warrants			539	977
Three Year Warrant [Member] | Convertible Notes Payable [Member]
Fair value of warrants				0
Five Year Warrant [Member]
Number of warrants to purchase common stock							2,500,000
Warrants, exercise price per share							$ 0.03
Warrants, expiration date							Mar. 3, 2021
Warrants, term							5 years
Fair value of warrants			$ 872	$ 491
Warrant [Member]
Warrants, exercise price per share	$ 0.001		$ 0.001
Warrants, intrinsic value	$ 0		$ 0
Stock price	$ 0.0005		$ 0.0005

Stock Warrants - Schedule of Wa

Stock Warrants - Schedule of Warrants Issued With Debt (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Number of Warrants	44,000,000	110,000,000	44,000,000
Fair Value of Warrants	$ 7,370	$ 8,147	$ 7,370	$ 0
Month of Expiration	August, 2020	August, 2019

Stock Warrants - Summary of War

Stock Warrants - Summary of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Weighted Average Exercise Price, Warrants, Beginning	$ 0.026
Weighted Average Exercise Price, Warrants, Ending	$ 0.0028	$ 0.026
Warrant [Member]
Number of warrants outstanding, Beginning	12,600,000	13,540,000
Number of warrants, Exercised
Number of warrants, Issued	154,000,000
Number of warrants, Expired	(114,100,000)	(940,000)
Number of warrants outstanding, Ending	52,500,000	12,600,000
Weighted Average Exercise Price, Warrants, Beginning	$ 0.026	$ 0.023
Weighted Average Exercise Price, Warrants, Exercised
Weighted Average Exercise Price, Warrants, Issued	0.001
Weighted Average Exercise Price, Warrants, Expired	0.0027	0.015
Weighted Average Exercise Price, Warrants, Ending	$ 0.0028	$ 0.026

Stock Warrants - Summary of Fix

Stock Warrants - Summary of Fixed Price Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Apr. 30, 2014	Sep. 12, 2013	Sep. 03, 2013	Mar. 31, 2013
Exercise Price			$ 0.025	$ 0.01	$ 0.025	$ 0.01
Weighted Average Exercise Price	$ 0.0028	$ 0.026
Minimum [Member]
Exercise Price	$ 0.001	$ 0.005
Weighted Average Number Outstanding	10,187,671	12,600,000
Weighted Average Contractual Life	7 months 13 days	1 year 1 month 9 days
Maximum [Member]
Exercise Price	$ 0.03	$ 0.05

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 30, 2018
Valuation allowance, increase (decrease) amount	$ 356,603	$ 3,748,415
Operating loss carry forward, net	37,100,000			$ 1,700,000
Income tax, description			In December 2017, the United States Government passed new tax legislation that, among other provisions, lowered the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income the Company may have, the legislation affects the way the Company can use and carryforward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on the balance sheet. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no net impact on the balance sheet. However, when the Company becomes profitable, the Company will receive a reduced benefit from such deferred tax assets.
Expired Between 2030 and 2037 [Member]
Operating loss carry forward, net	$ 35,400,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal tax rate	21.00%	21.00%
Add: State taxes	5.50%	5.50%
Permanent difference	(1.15%)	(1.15%)
Valuation allowance and change in federal tax rate	(25.35%)	(25.35%)
Tax rate	0.00%	0.00%

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Computed "expected" tax expense (benefit) - Federal	$ (1,384,203)	$ (793,340)
Computed "expected" tax expense (benefit) - State	(286,398)	(164,145)
Permanent differences	1,313,998	571,235
Change in federal tax rate		4,134,665
Change in valuation allowance	356,603	(3,748,415)
Provision for income taxes

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Reserve for prepaid inventory	$ 18,174	$ 12,104
Accrued salary	316,659	296,834
Reserve for receivables from officer	14,954
Net operating loss carryforwards	9,398,889	9,083,135
Valuation allowance	(9,748,676)	(9,392,073)
Net deferred income tax asset

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued consulting fees	$ 161,550	$ 161,550
Accrued settlement expenses	35,000	347,400
Accrued payroll taxes	167,906	120,182
Accrued interest	231,186	180,509
Accrued others	16,905	22,208
Total	$ 612,547	$ 831,849

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Future reserve for purchases	$ 23,948	$ 47,757
Total valuation allowance for prepaid	$ 224,859	$ 200,911

Prepaid Expenses - Schedule of

Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Supplier advances for future purchases	$ 224,859	$ 200,911
Reserve for supplier advances	(224,859)	(200,911)
Net supplier advances
Prepaid professional fees	8,650	13,000
Deferred stock compensation	8,500	50,000
Total	$ 17,150	$ 63,000

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

Feb. 15, 2019

Aug. 01, 2017

Apr. 12, 2017

Aug. 31, 2016

Feb. 28, 2016

Oct. 30, 2015

Aug. 17, 2015

Jul. 31, 2015

Jun. 01, 2015

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2016

Operating lease term

3 years

Operating lease due

$ 3,200

Lease expiration date

Feb. 28, 2019

Common stock shares issued

5,876,746,111

4,046,746,110

1,000,000

Note issued

$ 486,400

$ 348,050

Shares issued, price per share

$ 0.18

Accrued liabilities for commissions, expense and taxes

$ 142,500

Equity compensation charges

$ 31,750

Accrued expenses

$ 19,150

Share based compensation, shares not yet issued

1,500,000

Litigation term payment

$ 20,000

$ 20,000

Litigation term description

The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter.

Payment in event of default

$ 200,000

Gain (loss) related to litigation settlement

200,000

Accrued interest

$ 29,948

Loss contingency, allegations

The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company's issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company's stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.

Consulting Services Agreement [Member] | Restricted Stock [Member]

Consulting service term

5 years

Common stock shares issued

500,000

Debt instrument, interest rate,

8.00%

Note issued

$ 50,000

Consultant Agreement [Member]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted

2,500,000

Consultant Agreement [Member] | Common Stock [Member]

Debt instrument periodic payment

$ 3,000

Recepto Pharm Leases [Member]

Operating lease due

$ 6,900

Lease, description

ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year.

Patricia Meding [Member]

Litigation settlement, amount awarded to other party

$ 360,000

Litigation settlement term of payments

35 months

Paul Reid et al [Member]

Loss contingency, damages sought, value

$ 315,000

Get Credit Healthy, Inc. and Rik Deitsch,[Member]

Loss contingency, damages sought, value

$ 100,000

Long-term debt

101,818

Long-term debt, accured interest

$ 21,023

Payments for legal settlements

$ 104,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Lease Cost and Balance Sheet Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 89,021
Short-term lease cost	45,026
Total lease cost	134,047
Operating ROU Assets	207,530	$ 281,175
Operating lease obligations, current portion	73,278	64,573
Operating lease obligations, non-current portion	143,322	$ 216,602
Total operating lease obligations	$ 216,600
Weighted average remaining lease term (in years) - operating leases	2 years 8 months 2 days
Weighted average discount rate-operating leases	8.00%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 79,950

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Payments Under Lease Agreements (Details) - USD ($)	Dec. 31, 2019	Feb. 28, 2016
Total future lease payments		$ 3,200
Total	$ 216,600
Lease Agreements [Member]
2020	87,991
2021	91,379
2022	62,274
Total future lease payments	241,644
Less imputed interest	25,044
Total	$ 216,600

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jun. 22, 2021	Mar. 10, 2021	Dec. 31, 2020	Nov. 30, 2020	Nov. 30, 2017	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Sep. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020	Jun. 30, 2020	May 31, 2020	Apr. 30, 2020	Apr. 30, 2020	Mar. 31, 2020	Jan. 31, 2020	Jan. 31, 2019	May 31, 2017	Feb. 29, 2020	Apr. 30, 2021	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2020	Feb. 28, 2019	Apr. 30, 2014	Sep. 12, 2013	Sep. 03, 2013	Mar. 31, 2013
Warrants, exercise price per share																															$ 0.025	$ 0.01	$ 0.025	$ 0.01
Debt instrument accrued interest																											$ 66,460
Loss on settlement of debt																											92,621	905,758
Repayments of convertible debt																											13,500	3,000
Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount																											$ 511,319	$ 12,000
Settlement and Restatement of Promissory Notes[Member]
Debt instrument, face amount					$ 20,000
Number of shares issued					125,000,000
Minimum [Member]
Warrants, exercise price per share																											$ 0.001	$ 0.005
Warrant [Member]
Debt instrument, face amount																											$ 22,000			$ 70,000
Warrants, exercise price per share																											$ 0.001
Convertible Notes Payable [Member]
Debt instrument, original discount																											$ 22,344	$ 0		5,000
Warrants, exercise price per share																											$ 0.001
Number of warrants																											$ 8,147
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member]
Repayments of convertible debt																							$ 75,900
Convertible Notes Payable [Member] | Minimum [Member]
Debt conversion price																											$ 0.00010	$ .0002
Convertible Notes Payable [Member] | Note Agreement [Member]
Debt instrument, face amount																														$ 1,000,000
Proceeds from loan																											$ 372,374
Convertible Notes Payable [Member] | Warrant [Member]
Warrants, exercise price per share																											$ 0.001
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount																											$ 736,180
Debt instrument, original discount																											17,370
Convertible Notes Payable [Member] | Third Party [Member] | Restated [Member]
Debt instrument, face amount																							$ 75,900
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Debt instrument, face amount																											$ 12,629	$ 29,381
Debt instrument, interest rate,																								8.00%
Debt instrument, expiration or maturity date																								May 4, 2018
Subsequent Event [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount															$ 166,926
Debt instrument, due date															2021-01
Debt instrument, interest rate,															2.00%
Debt instrument accrued interest									$ 23,258
Number of shares issued									29,072,500
Number of shares issued, value									$ 343,056
Other income									319,798
Restated debt balance									183,619
Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount							$ 8,500																			$ 8,500
Debt instrument fair value							$ 15,200																			$ 15,200
Debt instrument accrued interest												$ 166,168
Number of shares issued							2,000,000
Number of shares issued, value							$ 4,000
Repayment of debt							4,500
Loss on settlement of debt							11,200
Subsequent Event [Member] | Settlement and Restatement of Promissory Notes[Member]
Debt instrument, face amount																					$ 50,000
Debt instrument, original discount																					$ 120,000
Debt instrument, due date																					2020-09
Number of shares issued																					36,000,000
Debt instrument, debt default, amount																					$ 84,000
Subsequent Event [Member] | Restated [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount									166,926						$ 148,225							$ 148,225
Debt instrument, original discount									$ 16,693
Debt instrument, due date									2021-08													2020-01
Debt instrument, interest rate,																						2.00%
Debt instrument accrued interest															$ 18,701
Subsequent Event [Member] | Restated [Member] | Settlement and Restatement of Promissory Notes[Member]
Debt instrument, face amount																					70,000
Debt instrument, original discount																					$ 14,000
Subsequent Event [Member] | Adjustments Decrease in Net Loss [Member] | Settlement and Restatement of Promissory Notes[Member]
Number of shares issued																					10,000,000
Number of shares issued, value																					$ 119,700
Subsequent Event [Member] | Unrelated Third Parties [Member] | Common Stock Issued for Default Payments [Member]
Debt instrument, face amount		$ 26,950
Debt instrument, original discount		$ 2,450
Debt conversion price		$ 0.01
Debt instrument, expiration or maturity date		Mar. 10, 2022
Subsequent Event [Member] | Two Year Loan Agreement [Member] | Payroll Protection Program [Member]
Proceeds from loan																		$ 64,895
Debt instrument, term																		24 months
Subsequent Event [Member] | Two Year Loan Agreement [Member] | Payroll Protection Program [Member]
Debt instrument, interest rate,																		1.00%
Subsequent Event [Member] | SBA Loan Agreement [Member] | Economic Injury Disaster Loan [Member]
Debt instrument, face amount													$ 731						$ 731	$ 731
Proceeds from loan																$ 154,900	$ 5,000		$ 154,900	$ 5,000
Debt instrument, interest rate,													3.75%						3.75%	3.75%
Subsequent Event [Member] | Warrant [Member]
Debt instrument, original discount				$ 7,500							$ 7,500
Warrants, exercise price per share				$ 0.002							$ 0.002
Number of warrants, granted				71,875,000
Number of warrants				$ 30,417							$ 30,417
Subsequent Event [Member] | Unrelated Third Parties [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount																						$ 60,000
Debt instrument, original discount																						$ 10,000
Debt instrument, interest rate,																						2.50%
Debt instrument accrued interest																						$ 88,225
Subsequent Event [Member] | Note Holder [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount								$ 11,000				$ 22,000	$ 22,000
Stock issued during period, restricted stock												107,817,770	107,133,333
Debt instrument accrued interest												$ 10,345	$ 10,140
Number of shares issued								11,000,000
Number of shares issued, value								$ 104,500
Remaining debt sold												$ 467,319
Repayment of debt								6,000
Loss on settlement of debt								98,500
Subsequent Event [Member] | Note Holder [Member] | Common Stock Issued for Default Payments [Member] | Restricted Stock [Member]
Stock issued during period, restricted stock										25,000,000		1,500,000	10,000,000		1,000,000							75,000,000
Stock issued during period, restricted stock value										$ 107,500		$ 900	$ 6,000		$ 700							$ 45,000
Repayments of convertible debt										$ 166,926		84,000	333,543		22,000							148,225
Subsequent Event [Member] | Note Holder [Member] | Repayments of Debt in Cash [Member] | Settlement of Convertible Promissory Notes [Member]
Repayment of debt								$ 5,000
Subsequent Event [Member] | Unrelated Third Party [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument accrued interest												250,000
Subsequent Event [Member] | Related Party [Member] | Settlement of a Related-Party Note [Member]
Debt instrument, face amount													14,400
Debt instrument, original discount													$ 2,400
Number of shares issued																5,000,000
Number of shares issued, value																$ 3,000
Repayment of debt																$ 14,400
Subsequent Event [Member] | Convertible Notes Payable [Member] | Minimum [Member]
Debt conversion price						$ 0.0008		$ 0.0003
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount						$ 265,650		$ 717,667
Debt instrument, original discount						$ 34,650		$ 93,609
Debt conversion price						$ 0.002		$ 0.002
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Agreement [Member]
Proceeds from loan	$ 122,362
Stock issued during period, restricted stock																										232,150,000
Stock issued during period, restricted stock value																										$ 116,075
Debt instrument fair value							2,292,809																			$ 2,292,809
Subsequent Event [Member] | Convertible Notes Payable [Member] | Warrant [Member]
Debt instrument, original discount												$ 29,481
Warrants, exercise price per share												$ 0.001
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount												$ 16,500		$ 38,500	20,900						68,750	68,750							$ 22,000
Debt instrument, original discount												$ 1,650		$ 7,550	$ 1,900						$ 6,250	$ 6,250							$ 2,000
Debt instrument, due date												2021-04		2021-02
Repayments of convertible debt							$ 19,500	$ 19,500
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder [Member]
Debt instrument, face amount				20,000		$ 100,810					20,000
Debt instrument, original discount												$ 9,200
Debt instrument, due date						2022-03									2021-01
Debt conversion price												$ 0.0005			$ 0.00052						$ 0.0005	$ 0.0005							$ 0.0003
Stock issued during period, restricted stock						237,850,000																			500,000,000
Stock issued during period, restricted stock value						$ 118,925																			$ 175,000
Debt instrument fair value				120,000		$ 2,328,149					$ 120,000														$ 425,000
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties One [Member]
Debt instrument, face amount														$ 22,000							$ 22,000
Debt instrument, original discount														$ 2,000							$ 2,000
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder One [Member]
Debt instrument, due date														2021-08
Debt conversion price														$ 0.0005							$ 0.0003
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties Two [Member]
Debt instrument, face amount														$ 5,500							$ 5,500
Debt instrument, original discount														$ 500							$ 500
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder Two [Member]
Debt instrument, due date														2021-02
Debt conversion price														$ 0.0005							$ 0.0002
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties Three [Member]
Debt instrument, face amount																					$ 5,500
Debt instrument, original discount																					$ 500
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder Three [Member]
Debt conversion price																					$ 0.0005
Subsequent Event [Member] | Convertible Notes Payable [Member] | Third Party [Member]
Debt instrument, face amount			$ 55,900
Debt instrument, due date			2021-01
Stock issued during period, restricted stock											100,000,000
Stock issued during period, restricted stock value											$ 20,000
Subsequent Event [Member] | Convertible Notes Payable [Member] | Three Unrelated Third Parties [Member]
Debt instrument, face amount				208,800							208,800
Debt instrument, original discount				$ 19,800							$ 19,800
Debt conversion price				$ 0.0005							$ 0.0005
Subsequent Event [Member] | Convertible Notes Payable [Member] | Three Unrelated Third Parties [Member] | Minimum [Member]
Debt conversion price				$ 0.00022							$ 0.00022
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount				$ 139,150							$ 139,150
Debt instrument, original discount				$ 12,650							$ 12,650
Debt conversion price				$ 0.00055							$ 0.00055
Subsequent Event [Member] | Two Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount			$ 57,500	$ 57,500							$ 57,500
Debt instrument, original discount			$ 7,500	$ 7,500							$ 7,500
Debt conversion price			$ 0.0008	$ 0.0008							$ 0.0008

Subsequent Events - Summary of

Subsequent Events - Summary of Warrants Issuance (Details) - USD ($)	1 Months Ended				12 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of Warrants			44,000,000	110,000,000	44,000,000
Fair Value of Warrants			$ 7,370	$ 8,147	$ 7,370	$ 0
Month of Expiration			August, 2020	August, 2019
Subsequent Event [Member] | Warrant [Member]
Number of Warrants	39,930,000	92,100,000
Fair Value of Warrants	$ 8,633	$ 20,848
Month of Expiration	October, 2022	August, 2021

Subsequent Events - Schedule of

Subsequent Events - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Jun. 01, 2021	Apr. 26, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Mar. 03, 2020	Feb. 18, 2020	Jan. 21, 2020	Jun. 06, 2019	May 31, 2019	May 06, 2019
Number of shares converted									250,000,000	250,000,000	250,000,000
Fair value of debt converted									$ 100,000	$ 100,000	$ 75,000
Subsequent Event [Member] | Note Holder [Member]
Number of shares converted	5,700,000	27,070,000	137,700,000	107,817,770	107,133,333	67,380,000	250,000,000	250,000,000
Fair value of debt converted	$ 35,340	$ 192,197	$ 1,500,930	$ 64,691	$ 171,413	$ 599,682	$ 275,000	$ 150,000